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ABSTRACT  
   
Cell heterogeneity is widely present in the biological world and exists even in an 
isogenic population. Resolving the protein heterogeneity at the single cell level is of 
enormous biological and clinical relevance. However, single cell protein analysis has 
proven to be challenging due to extremely low amount of protein in a single cell and the 
huge complexity of proteome. This requires appropriate sampling and sensitive detection 
techniques. Here, a new approach, microfluidics combined with MALDI-TOF mass 
spectrometry was brought forward, for the analysis of proteins in single cells. The 
detection sensitivity of peptides as low as 300 molecules and of proteins as low as 10
6
 
molecules has been demonstrated. Furthermore, an immunoassay was successfully 
integrated in the microfluidic device for capturing the proteins of interest and further 
identifying them by subsequent enzymatic digestion. Moreover, an improved 
microfluidic platform was designed with separate chambers and valves, allowing the 
absolute quantification by employing iTRAQ tags or an isotopically labeled peptide. The 
study was further extended to analyze a protein in MCF-7 cell lysate. The approach 
capable of identifying and quantifying protein molecules in MCF-7 cells is promising for 
future proteomic studies at the single cell level. 
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CHAPTER 1  
INTRODUCTION 
1.1 Significance of Single Cell Analysis 
Cellular heterogeneity within a given cell type or in an ensemble of isogenic cells 
is a widespread event. Understanding such heterogeneity in single cells promotes 
development in many fields including molecular biology, cancer diagnostics, pathology 
and therapy. Protein detection and quantification of individual cells are mainly performed 
with large cell populations averaging quantitative information over a large cellular 
ensemble, or is limited to the investigation of few cells at a time. However, in many 
instances, the qualitative and quantitative information obtained from the measurement of 
an averaged cell population mask the true behavior of the individual cells. Thus, single 
cell analysis is crucial for resolving cellular heterogeneity and understanding cell-to-cell 
variations. 
A striking example between single cell and population cell measurements is 
exemplified in Figure 1-1a. In response to DNA double strand breaks (DSBs), undamped 
p53 pulses with fixed amplitude and duration are seen in individual cells. By contrast, 
measurements averaged over populations of cells show damped oscillations of 
p53(Batchelor, Loewer, and Lahav 2009). Cellular heterogeneity among single cells is 
also shown with hormones. Individual oocytes show discrete all or nothing response for 
an intermediate level of progesterone stimulation while the physical models predict an 
intermediate level of commitment for an intermediate level of progesterone stimulation 
for oocytes (Ferrell and Machleder 1998; Altschuler and Wu 2010). Another example 
related to siRNA GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) gene expression 
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also shows that the behavior of individual cells is different from the population average 
(Figure 1-1b). The last example is about individual Jurkat cells which present two distinct 
populations of cells with either partial knockdown (~50%) or complete knockdown (~0%) 
however averaged bulk measurements from 50 cells show GAPDH expression at ~21% 
(Toriello et al. 2008). These examples clearly demonstrate that single cell analysis offers 
fascinating possibilities to illuminate cellular heterogeneity and diversity.   
 
Figure 1-1: Examples of cellular heterogeneity. a. Average response in the population of 
cells show p53 damped oscillations but responses in individual cells show different 
numbers of undamped pulses. Adapted with permission from Batchelor et al.(Batchelor, 
Loewer, and Lahav 2009). b. GAPDH gene expression for Jurkat cells. 8 individual cells 
exhibit either ~50% or~ 0% GAPDH expression level. A control with no cell (0 cells) 
exhibit no products. A PCR control without reverse transcriptase (no RT) show no signal. 
Averaged bulk measurements from 50 cells show GAPDH expression at ~21%. Adapted 
with permission from Toriello et al. (Toriello et al. 2008). 
 
Three more application-driven examples are cited here. First example is about 
understanding the steps of cell development such as assessing individual stem cells. Stem 
cells have the remarkable potential for treating disease (referred to as regenerative 
medicine) due to their unique long-term self-renewal and proliferation abilities (Hirschi, 
Li, and Roy 2014; Mull, Zolekar, and Wang 2015; Nakajima-Takagi, Osawa, and Iwama 
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2014). However, stem cells are all heterogeneous populations such as embryonic stem 
cells or adult stem cells (Graf and Stadtfeld 2008; Takahashi et al. 2007). Single cell 
analysis can target specific cell populations and thus allows unraveling the signaling 
pathways and networks for self-renewal and for differentiation (Wang and Bodovitz 
2010).  
The Second example is in cancer diagnostics and treatment. Fundamental insights 
of cancer research are also offered through single cell analysis since cancer is a 
heterogeneous disease. Acquainting with tumor initiation, metastasis and response to a 
drug in single tumor cells is extremely important for cancer treatment (Wang and 
Bodovitz 2010; Martinkova et al. 2009; Majewski and Bernards 2011). Circulating tumor 
cells (CTCs) have been demonstrated to be prognostic for metastatic breast cancer 
(Massimo Cristofanilli 2004). Single cell analysis can analyze single CTCs enriched from 
patient blood samples such as based on RT-MLPA (Reverse Transcriptase Multiplex 
Ligation-dependent Probe Amplification) assay (Kvastad et al. 2015). This can 
potentially be a diagnostic tool for cancer genomics. Other examples for single cell 
analysis of CTCs were summarized in a good review by XiXi et al. (XiXi Chen 2015). In 
addition, it has been proven that the protein expression level in single cells is highly 
associated to cancer progression and metastasis. For example, the elevation of c-Src level 
is known to be associated to cancer progression. Moskaluk et al. reported that the c-Src 
protein expression was increased by 30-fold in human breast cancer cells compared to 
normal breast tissue (Verbeek et al. 1996) and thus c-Src could be potentially a biomarker 
for human breast cancer. Sano et al. demonstrated that over- expression of p16 was 
associated with cervical cancer (Shapiro et al. 1995). Similarly, quantitative analysis of a 
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particular protein in a single cell can improve the early diagnosis of diseases like cancer 
originating from a single cell (Roncador et al. 2005). 
The third example is in neuroscience. Neurons are the basic unit of the nervous 
system which are extremely heterogeneous. The molecular complexity of neuropeptides 
and neuroproteins are just being understood (Odowd and Smith 1996). Sweedler's group 
analyzed releases from a single neuron which helped elucidate neural communication and 
neurological disorders (Fuller et al. 1998; Fan et al. 2013; Page, Rubakhin, and Sweedler 
2002; Rubakhin, Greenough, and Sweedler 2003). 
 
1.2 Challenge of Single Cell Proteome Analysis 
Although currently available approaches can potentially provide snapshots of 
single cells, there is still an increasing need for analysis of extremely low sample amount 
at the level of single cells. This need is particularly urgent when the number of cells is 
limited (e.g. stem cells, early stage embryos). The vast majority of commercial products 
for single cell analysis focus on DNA and RNA. An example is Fluidigm Inc. 
(www.fluidigm.com) selling different polymerase chain reaction (PCR) systems 
providing automated solution for single-cell genomics. Single cell genomic analysis has 
been greatly aided by amplification techniques such as PCR (Li et al. 1988; Lambolez et 
al. 1992) and isothermal amplification (Kurn et al. 2005). This was recently reviewed by 
Quake et al. (Kalisky, Blainey, and Quake 2011). Compared with single cell genome 
analysis, protein analysis on the single cell level has proven to be more challenging due 
to extremely small amounts of protein in a single cell (Beck et al. 2011) and the 
tremendous complexity of the proteome. Copy numbers of proteins in single mammal 
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cells vary from several tens to a million copies (Xie et al. 2008; Hanke et al. 2008), which 
is vanishingly low. The lack of amplification techniques makes analysis of proteins in a 
single cell more difficult. Moreover, one gene does not only produce one protein. One 
example is that a single gene in Drosophila can potentially encode more than 30000 
closely related but distinct proteins (Clark et al. 2007). This kind of complexity stems 
from many attributes including protein abundance and expression levels, enzymatic 
activity, post-translational modification, interaction with other proteins, and protein 
secretion and translocation (Wu and Singh 2012).  
 
1.3 Current Single Cell Proteome Analysis Status 
The traditional methods for single-cell sample processing such as microdissection 
and micromanipulators have a disadvantage of low throughput. Microfluidic or lab-on-a-
chip devices can achieve high throughput analysis and are especially suitable for handling 
ultra-small sample volumes (in the nano to pico liter range) comparable to the size of a 
single cell (Whitesides 2006). In comparison to alternative capillary-based approaches 
(Arcibal, Santillo, and Ewing 2007; Cannon, Winograd, and Ewing 2000; Stuart and 
Sweedler 2003), microfluidic devices simplify cell-handling techniques and more 
importantly allow parallelization as well as the integration of a variety of necessary 
workflow steps involved in cellular analysis, such as selection, navigation, positioning 
and lysis as well as separation of cellular analytes (Roman and Kennedy 2007; Sims and 
Allbritton 2007; Roman et al. 2007; Chao and Ros 2008). Furthermore, microfluidic 
volume control further allows the combination of sensitive protein detection via 
fluorescence methods with cellular manipulation in microenvironments close to the 
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intrinsic volume of a single cell, thus advantageously preventing dilution in sampling 
steps.  
A recent example is the work of Dittrich and coworkers reporting a microfluidic 
platform (Eyer et al. 2012) coupled with enzyme-linked immunosorbent assays (ELISA) 
suitable for analysis of proteins and metabolites in single mammal cells (Eyer et al. 2013). 
They further downscaled the device for probing intracellular enzymes in single bacteria 
as shown in Figure 1-2 (Stratz et al. 2014).  They developed a cell trap with a ring valve 
integrated for trapping a single Escherichia coli bacterium. The target enzyme from the 
Escherichia coli bacterial lysate was captured by antibodies immobilized on the surface 
for further detection. Another example is related to droplet-based (digital) microfluidics 
which has recently been applied to MALDI MS (matrix assisted laser desorption 
ionization mass spectrometry) analysis. Multiple sample manipulation steps can be 
integrated in one device including sample preparation, matrix deposition as well as 
purification (Wheeler et al. 2005; Nelson et al. 2010; Moon et al. 2006; Chatterjee et al. 
2010). Compartmentalization of single cells from droplets allows the analysis of proteins 
released from cells, thereby overcoming the major limitations of traditional flow 
cytometry. Mazutis et al. detailed a binding assay for detecting antibodies from single 
mouse hybridoma cells as depicted in Figure 1-3. Only 15 min was needed for antibody 
detection after co-compartmentalizing single mouse hybridoma cells (Mazutis et al. 
2013). However, digital microfluidic platforms require sophisticated designs and 
electrode integration.   
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Figure 1-2: Workflow of β-galactosidase analysis in a single Escherichia coli bacterial. 
The ring shaped valve is designed for isolation of a single Escherichia coli bacterial.  
A single Escherichia coli bacterial expressing β-galactosidase is trapped, isolated and 
finally lysed. An immunoassay is performed on the surface to capture β-galactosidase. 
After a washing step, the enzyme (β-galactosidase) is detected by adding the β-
galactosidase substrated FDG that is converted to highly fluorescent fluorescein. Adapted 
with permission from Stratz et al. (Stratz et al. 2014) 
 
Furthermore, microfluidic technology can be combined with a variety of 
analytical detection schemes. The most widely used detection technique for protein 
quantification in single-cells is based on fluorescence measurements due to their high 
sensitivity such as laser-induced fluorescence (LIF) which can usually achieve detection 
limits in the pM range (Lee and Yeung 1992). Dovichi’s group even achieved sub-
attomole amino acid analysis by capillary zone electrophoresis combined with LIF 
(Cheng and Dovichi 1988). Recently, they pioneered the use of a sheath flow cuvette in a 
capillary electrophoresis-laser induced fluorescence (CE-LIF) system decreasing the limit 
of detection to less than 100 molecules (Dada, Huge, and Dovichi 2012). Besides, they 
published several articles for analyzing chemical contents of individual cells by two-
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dimensional capillary electrophoresis (Harwood et al. 2007; Sobhani et al. 2007). 
Nevertheless, high throughput analysis has not been realized in CE-LIF.  
 
Figure 1-3: Antibody detection from single mouse hybridoma cells. Two types of cells 
are introduced with a bead suspension. The bead suspension contains goat detection 
antibodies which are labeled with green fluorescent dyes and the beads are coated with 
goat anti-mouse-Fc capture antibodies. One cell type produces mouse antibodies (grey) 
and the other (orange) does not. The droplets are generated by flow focusing with 
fluorinated oil containing fluorosurfactant. The cell suspension and the bead suspension 
can only mix inside the droplets due to laminar flow. Then the droplets are collected off-
chip at 4°C. After incubation for 15min at 37°C and 5% CO2, those beads which were 
encapsulated with an antibody-producing cell are highly fluorescent. The droplets are 
then introduced into a second microfluidic device and sorted using a fluorescent activated 
droplet sorter. Three microscope images below show the coencapsulation of cells with 
beads (left), droplets introducing to the second microfluidic device (middle), and droplet 
sorting (right). Adapted with permission from Mazutis et al. (Mazutis et al. 2013) 
 
Flow cytometry with fluorescence activated cell sorting (FACS) is a potent 
highthroughput technique for single cells analysis. In this approach, fluorescence signals 
from fluorescent antibodies which are attached to the cell membrane antigens can be 
  9 
monitored. A typical FACS workflow is shown in Figure 1-4 (Pedreira et al. 2013). This 
fluorescence signal from the detector is converted to an electrical signal, trigging the cell 
sorting in FACS. For example, it has been employed for the detection of mammalian β-
glucuronidase activity at the single cell level (Lorincz et al. 1999). Furthermore, FACS 
can be used to analyze multiple proteins simultaneously in single cells due to the 
development of highly specific antibodies. Freer et al. detected 18 different colors of 
fluorescent antibodies in peripheral blood mononuclear cells, making it the only 
immunological technique allowing simultaneous determination of antigen-specific T cell 
function and phenotype (Freer and Rindi 2013). The Nolan group reported simultaneous 
measurement of the activation states of kinases within single cells by using a FACS-
based strategy (Perez and Nolan 2002). They used multiparameter flow cytometry to 
monitor phospho-protein responses at the single cell level (Irish et al. 2004).  However, 
since the number of fluorescent dyes suitable for FACS experiments is limited, the 
number of proteins that can be studied by this approach is quite restricted. 
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Figure 1-4: Workflow of FACS. Individual cells are forced to pass a small tube one-by 
one. Three different detectors (FSC: forward light scatter for collecting light at low 
angles; SSC: sideward light scatter and fluorescence detector to collect light and 
fluorescence) are placed into different positions. Adapted with permission from Pedreira 
et al. (Pedreira et al. 2013). 
           
In comparison to fluorescence detection, mass spectrometry based single-cell 
analysis can potentially provide label-free analysis of a single cell. Sweedler's group 
developed a sensitive and robust capillary electrophoresis-electrospray ionization mass 
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spectrometry (CE-ESI MS) system suitable for investigation of metabolites at the single 
cell level (Nemes et al. 2011, 2012). Matrix assisted laser desorption and ionization- time 
of flight (MALDI-TOF) mass spectrometry is a powerful technique which has been 
widely used in the field of biomarker discovery (Calligaris, Villard, and Lafitte 2011; 
Chao, Hansmeier, and Halden 2010; Lu et al. 2012). Excellent sensitivity of this method 
has been demonstrated  not only for metabolites (Amantonico et al. 2008; Miura et al. 
2010) but also for peptides (Nordhoff, Lehrach, and Gobom 2007; Dong et al. 2010) and 
even proteins (Hanke et al. 2008). The matching of apparent protein copy numbers with 
the detection sensitivity of mass spectrometers has stimulated attempts to analyze single 
cells with both electron spray ionization (ESI) (Hofstadler et al. 1996; Cao and Stults 
1999) as well as matrix assisted laser desorption/ionization (MALDI) (Rubakhin et al. 
2006; Jo et al. 2007; Li, Golding, and Whittal 1996).  Furthermore, it permits 
identification and characterization of the analyte and moreover provides quantitative 
information on the level of peptides formed by the cleavage and digestion of target 
proteins. Bai et al. found that the MALDI MS/MS spectra provided sufficient information 
for the identification of the studied peptides by analyzing the intensity of the fragment 
ions (Bai, Romanova, and Sweedler 2011).   
Moreover, iTRAQ (isobaric tag for relative and absolute quantitation) tags have 
been implemented widely as a quantitative MALDI MS technology especially in 
discovery-based proteomics (Noirel et al. 2011) utilizing isobaric reagents with different 
stable isotope compositions (Ross et al. 2004; Merali et al. 2014; Treumann and Thiede 
2010). This technology has been successfully adapted for the relative quantification of 
peptides from individual A. californica neurons (Rubakhin and Sweedler 2008) . 
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However, acquiring quantitative information of proteins from single cells by iTRAQ 
strategies has not been reported.  
In this thesis, a label free detection and high throughput method was developed, 
combining the advantages of a sensitive mass analyzer (MALDI-TOF) and microfluidic 
technology. This combined approach may eventually allow the identification and 
quantificaton proteins from single cells in parallel thus improving our capability in 
understanding the protein functions, drug design and cancer diagnostics in early stages. 
 
1.4 Dissertation Objective 
 
Figure 1-5: Scheme of entire microfluidic platform for single cell analysis. Fluidic 
channels (white channels enframed by black lines) in PDMS layer 1 are employed for 
single cell trapping, cell lysis, delivery of enzyme for enzymatic digestion and MALDI 
matrix deposition. Pneumatic valves (Blue squares) are in PDMS layer 2 for separating 
fluidic channels into separate regions. The black arrows indicate the workflow direction. 
The objective of this dissertation is to develop a novel approach for single cell 
protein analysis based on the coupling of a multilayer microfluidic device with MALDI 
mass spectrometry. This approach will eventually allow resolving protein heterogeneity 
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at the single-cell level and thus potentially improving our current status in understanding 
the protein functions, drug design and cancer diagnostics.  
The entire microfluidic platform is shown in Figure 1-5 for trapping a single cell 
and analyzing target proteins from cell lysate. This thesis mainly focuses on lysing the 
cells and analyzing target proteins from the cell lysate. Specifically, affinity capture 
regions are integrated for capturing proteins of interest from cell lysate.  Enzymatic 
digestion is performed for protein identification and quantification on the level of 
peptides formed by the cleavage and digestion of target proteins. The last step is MALDI 
matrix deposition prior to MALDI MS analysis.  
As discussed in Section 1.2, the complexity of the proteome requires powerful 
separation steps prior to analysis. This complexity can influence the subsequent MALDI 
MS detection of target proteins. Thus in this device, we take advantage of specific 
immunoreactions capturing the proteins of interest from cell lysate. MALDI-TOF MS is 
chosen as the detection technique to provide label-free detection. The sensitivity of 
MALDI MS is suitable for single cell analysis (Amantonico et al. 2008). In addition, 
absolute protein quantification can be realized by MALDI-TOF detection on the level of 
peptides formed by digestion of target proteins, allowing the study of protein expression 
levels in single cells. Moreover, this microfluidic device enables integration of necessary 
process steps involved in single cell analysis prior to MS analysis and thus simplifies 
tedious single cell handling techniques. It can confine samples in the necessary small area 
effectively preventing dilution and making the whole approach suitable for single cell 
analysis. More importantly, compared to capillary-based approaches, more parallel 
channels can be integrated, allowing high throughput analysis.   
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Background and theory are discussed in chapter 2. Hyphenation of a microfluidic 
platform and MALDI-TOF detection is demonstrated in chapter 3. Protein identification 
and quantification by two different methods are discussed in chapter 4 and 5. Analysis of 
proteins in MCF-7 cells with the proposed approach is described in chapter 6. 
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CHAPTER 2  
FUNDERMENTALS AND THEORY 
2.1 Immunoassays  
An immunoassay represents a purification method to measure the presence of 
biomolecules (typically a protein) in complex samples by using their antibodies (Ab) also 
known as immunoglobulins. The molecule recognized by an antibody is called an antigen 
(Ag). There are five isotypes of antibody in mammals: IgA, IgD, IgE, IgG and IgM. IgG 
provides the majority of immune reactions towards invading pathogens. IgG is a Y-
shaped protein containing two light chains and two heavy chains (Figure 2-1). Each light 
chain has a molecular weight of ~ 25,000 Da and consists of two domains, one constant 
domain and one variable domain. Each heavy chain has a molecular weight of 
~50,000 Da and contains either three or four constant domains and one variable domain. 
An IgG can be cleaved by the enzyme papain into two antigen-binding fragments (Fab) 
and one crystallizable fragment (Fc). The Fab region contains variable sections that can 
determine the type of the target that the IgG can bind. In contrast, the Fc region is 
constant for all antibodies within the same animal class. A specific region on the antibody 
is called paratope. A particular region called epitope on an antigen is always specific to 
the paratope on the antibody, allowing the binding of these two structures precisely. The 
interaction between antibody and antigen is through a specific interaction including 
electrostatic interactions, hydrogen bonds, Van der Waals forces and hydrophobic 
interactions. Each antibody binds specifically to only one antigen. The specificity 
originates from the unique amino acid sequence in the antibody (paratope) and the 
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epitope on the antigen. The binding process for antigen and antibody is a dynamic 
equilibrium (Eq. 2-1): 
                                                                                      (2-1) 
Where Ab represents antibody , Ag represents antigen and AgAb represents antigen-
antibody complex. 
Understanding the specificity and the affinity strength of antibody-antigen 
binding are fundamental for studying the activity of these proteins. The binding constant 
Ka (Eq. 2-2) and the dissociation constant Kd (Eq. 2-3) are often used to characterize the 
affinity of antibody-antigen interaction. Apparently, they have reverse relationship. The 
smaller the Kd (the larger the Ka), the stronger the binding between the antibody and 
antigen. Kd typically ranges from 10
-9
 to 10
-11
 which means that the binding complex 
dominates in the immunoreactions.    
                                         
      
        
                                           (2-2)                                
                                         
        
      
                                           (2-3) 
 
Figure 2-1: Scheme of antibody- antigen interaction. The IgG is a Y-shaped protein 
which has two light chains and two heavy chains. The positions binding to the antigen are 
on the tips of the antibody. 
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In the immunoassay, antibodies are often required to be immobilized on the 
surface with proper orientations allowing the high antigen-antibody binding efficiencies 
(Lee et al. 2013). Random orientation of antibodies can result in the loss of binding 
ability. For IgG, the ideal orientation is that the antibody is immobilized vertically to the 
surface which the paratopes (antigen binding sites) are exposed to the antigens.  There are 
a wide variety of protein immobilization methods that have been reported (Kim and Herr 
2013). A particular antibody immobilization method is chosen depending on various 
factors including the immobilization surface, antigen property, buffer components and the 
requirements of the assay such as sensitivity, selectivity and reproducibility. Antibody 
immobilization is often realized based on three binding mechanisms including physical 
adsorption, bioaffinity interaction, covalent bonding.  
The simplest approach to immobilize antibodies on a surface is through physical 
adsorption. The antibodies can be attached to various surfaces via intermolecular forces 
such as electrostatic, hydrophobic, van der Waals forces.  Generally, incubation of 
antibodies in solution contacting the immobilization surface or continuous flow of the 
antibody solution can attach the antibodies on the surface. Physical adsorption is often 
weak since there are no covalent bonds linking the antibody to the antigen. 
The antibody immobilization based on bioaffinity interaction exploits specific 
binding phenomena existing in nature. Bioaffinity interactions are often used in 
conjunction with the other two immobilization mechanisms (physical adsorption and 
covalent bonding).  The surface and the antibody are linked via a bioaffinity agent which 
is used as the intermediate. Avidin/streptavidin-biotin can be used as the bioaffinity agent 
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to immobilize antibodies. Streptavidin/avidin binds strongly with biotin acting as small 
ligands through coordination. The dissociation constant for avidin-biotin system is on the 
order of 10
-15
 M while the dissociation constant for streptavidin-biotin is on the order of 
10
-14
 M (McMahon 2008). Wang et al. reported a bead-based immunoassay which was 
employed to detect proteins (Wang and Han 2008).  Biotinylated GFP (green fluorescent 
protein) and R-PE (R-phycoerythrin) antibodies were attached to commercial 
streptavidin-coated beads to preconcentrate the biotinylated GFP and R-PE proteins. 50 
pM to 10 fM detection limit was observed for both proteins. 
Covalent bonds are frequently used to immobilize antibodies on the surface. The 
surface is activated by a specific chemical reagent, forming irreversible binding with 
antibodies. One of the most commonly used covalent linking agents is N-
hydroxysuccinime (NHS) ester which can react with amines on proteins (Rusmini, Zhong, 
and Feijen 2007). Delamarche et al. reported antibody immobilization by NHS ester in 
microfluidic device (Delamarche et al. 1997). The surface of the glass or the silicon wafer 
was coated with aminosilane. The amine functional groups of the aminosilane were 
linked to the NHS ester for antibody immobilization. Epoxide is another functional group 
in covalent linking agents used for antibody immobilization. It can form covalent bonds 
with primary amines on proteins. One example is that the commercial HER2 antibody 
which was attached to the surface via epoxide group of the allyl glycidyl ether (AEG) 
polymer, allowing the subsequent capture of circulating tumor cells (CTCs) (Thierry et al. 
2010). 
The antibodies that bind to the antigens or proteins directly are called primary 
antibodies while the ones that bind to the primary antibodies are secondary antibodies. 
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Secondary antibodies are used to assist in detection of the target antigens and they are 
very efficient in immunolabeling. Secondary antibody binds to the primary antibody via 
its Fab domain (Figure 2-1) to the Fc domain (Figure 2-1) of primary antibody. In the same 
animal class, the Fc domain is constant. Thus, one type of secondary antibodies can bind 
to many types of primary antibodies. In this way, instead of labeling many types of 
primary antibodies, only one type of secondary antibody is required, which reduces the 
cost and simplifies the labeling procedures.  
Antibodies are used throughout various types of assays including western blot, 
enzyme-linked immunosorbent assay (ELISA), flow cytometry and 
immunohistochemistry. In terms of different detection methods, immunoassays are 
performed in different formats. There are many different detectable labels that can be 
used in the immunoassays. One major type of the labels is the enzyme. This type of 
immunoassay employing enzymes is the ELISA. The enzyme can catalyze a certain 
reaction, producing a color change to detect the presence of a substance. The enzymatic 
reactions provide signal amplification which can increase the detection limit and 
sensitivity. The ELISA has been used as a diagnostic tool (such as HIV test). A second 
major type of detectable label is fluorophore. With fluorescence emission, the distribution 
of antigens can be revealed using optical microscopy. A third major type of detectable 
label is radioactive isotopes. Radioactive isotopes can go through radioactive decay, 
emitting alpha, beta or gamma rays which can be revealed by autoradiography. 
Immunoassays have been used in single cell proteome analysis (Eyer et al. 2013; 
Casey et al. 2010; Zhang and Jin 2006). An example (Stratz et al. 2014) is mentioned in 
Chapter 1.4 (Figure 1-2) demonstrating the integration of ELISA (enzyme-linked 
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immunosorbent assay) to capture the β-galactosidase from a single Escherichia coli 
bacterium. Choi et al. reported an improved immunoassay for the detection of cytokines 
released from human peripheral mononuclear cells. The detection sensitivity was 
enhanced by 200 fold by detecting the cytokines antibodies with covalently attached 
fluorescent oligomers (Choi et al. 2011). 
2.2 MALDI Mass Spectrometry  
MALDI mass spectrometry was invented in late 1980s (Karas et al. 1987). The 
introduction of MALDI mass spectrometry is a milestone in the history of mass 
spectrometry. It can provide soft desorption and ionization for sample molecules which is 
important for analysis of biomolecules. The key part of MALDI to be successful is the 
application of matrix which can assist the intact desorption and ionization of 
biomolecules.  
In MALDI, matrix molecules are usually organic, aromatic and conjugated 
compounds. The sample molecules are dissolved into the matrix solution and they co-
crystallize in the drying process. In this co-crystallization process, sample molecules are 
incorporated into the matrix crystals. A specific laser wavelength is used so that photons 
can only be absorbed by the matrix molecules while the sample molecules have little 
absorption. After the absorption of the laser photons, the matrix molecules become very 
hot (>1000K) and expand. The whole process is accomplished in a short time (~ps) 
which results in supersonic explosion (velocity reaches at km/s) (Chou, Nelson, and 
Williams 2009). The explosion of the matrix crystals carries sample molecules into the 
gas phase. The sample molecules are desolvated during this process. The supersonic 
expansion has a cooling effect on the sample molecules preventing fragmentation. The 
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ionization mechanism is believed to be associated with proton transfer. Under the high 
temperature after photon absorption, free protons are dissociated from matrix molecules 
(weak acid). The basic groups in the sample molecules tend to associate with the free 
protons to become ionized. Figure 2-2 shows a typical process of laser desorption and 
ionization (For illustration purposes, the figure is not drawn to scale, the laser beam is 
usually ~100µm which is much bigger than sample molecules)  
 
Figure 2-2: General principle of MALDI. Sample molecules are co-crystallized with 
matrix molecules. Desorption and ionization of sample molecules occurs after the matrix 
molecules absorb the laser photon. Sample ions are extracted by the extraction electric 
field into the mass spectrometer. For illustration purpose, the size of laser beam (~100µm) 
is much smaller than it should be compared with sample or matrix molecules. 
 
MALDI is usually coupled with a time of flight mass analyzer (e.g. TOF: time of 
flight), depicted as Figure 2-3. Ions leaving the sample surface are extracted by a static 
electric field (several kVs) into the field free drift zone. Ions with same number of 
charges will have the same total kinetic energy entering the drift zone. But due to the 
difference in the mass to charge ratio, their flight velocities are different. Ions with larger 
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m/Z have smaller velocity, thus needing a longer time to arrive the detector (equation 2-4, 
2-5, 2-6). Based on their flight times, the corresponding m/Z can be calculated.  
 
 
                                  
 
 
                                  (2-4) 
                                
   
 
                                                                   (2-5) 
              
 
 
    
 
   
    
   
   
                              (2-6) 
Where E is the static acceleration electric field strength; e is the number of 
charges carried by the ion; m is the mass of the ion; v is the velocity of ion flying in the 
TOF; L is the flight length in the TOF; m/Z is the mass to charge ratio of the ion. 
In sophisticated MALDI-TOF instruments, reflectrons are used to minimize the 
initial energy spread due to the sample desorption, improving the mass resolution (Figure 
2-3). Ions with bigger initial energy will fly through a longer pathway in the reflectron 
resulting in longer flight time. The MALDI-TOF detection system usually uses a micro-
channel plate. For heavier ion detection, post-acceleration is usually required in order for 
ions to have enough energy producing secondary electrons after hitting the channel plate 
surface. Secondary electrons are extracted and amplified through the microchannel. The 
amplified electric signals are detected by the electronics system and are counted as counts 
of ions.  
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Figure 2-3: Scheme of MALDI-TOF mass spectrometer. After shooting the sample 
surface with laser beam, molecular ions are desorbed and extracted into the mass 
spectrometer. After entering into the time of flight tube (drift zone), the ions start flying 
with velocities corresponding to its mass to charge ratio. Reflectron is used to minimize 
the initial energy spread of ions coming out the sample surface. Heaver ions with bigger 
mass to charge ratio arrive at the detector later than the light ions. According to the ions' 
flight time arriving at the detector, their mass to charge ratios can be calculated. 
 
MALDI is also employed in tandem mass spectrometry (also known as MS/MS) 
such as a MALDI TOF/TOF system. In tandem mass spectrometry, there are two mass 
analyzing stages involved and a fragmentation process occurs between these two stages. 
In the first stage (MS1), samples are ionized and desorbed in the ionization source (e.g. 
MALDI). And the ion species are separated according to their mass to charge ratios by 
the first mass analyzer (e.g. TOF). Ions with a specific mass to charge ratio are selected 
as the precursor ions. These precursor ions are further fragmented and the fragment ions 
(product ions) are created which will be separated by the second mass analyzer (e.g. 
TOF). Afterwards, the product ions are detected by the detector (e.g. microchannel 
plates). The workflow about MALDI TOF/TOF detection is shown in Figure 2-4. From 
the peaks of product ions in MS/MS spectrum, the structure and composition of the 
precursor molecules are obtained. 
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 There are three commonly used methods for precursor ions fragmentation in 
tandem mass spectrometry. The first one is called collision-induced dissociation (CID). 
In this method, a gas collision cell is usually added to the ion drifting pathway. When the 
ions fly through the gas collision cells, the ions collide with the gas molecules and 
become fragmented. Another method is post-source decay (PSD). Ions with internal 
energy leaving the sample surface can self-fragment in the flying process generating 
fragment ions. This method does not require additional instrumentation and is therefore 
used in this thesis. The third method is through photon absorption which can induce the 
dissociation reaction.  
 
Figure 2-4: Workflow for the sample in MALDI TOF/TOF instrument. Sample is ionized 
and separated in the first TOF analyzer. Ions with a certain mass to charge ratio are 
selected as the precursor ions which are subsequently fragmented into small ions. These 
small ions are separated in the second mass analyzer and finally detected. 
 
As mentioned, MALDI is a very powerful technique for detection of biomolecules 
due to the ability of desorption and ionization of intact molecules. MALDI imaging is 
one of the most popular imaging mass spectrometry methods. It has been used widely for 
lipids, peptides and proteins imaging in disease diagnosis. Caprioli et al. used MALDI 
imaging to image hundreds of proteins from a human breast carcinoma section (Seeley 
and Caprioli 2008), as shown in Figure 2-5. Three different proteins (Histone H2A, 
Calgizzarin  and Thymosin β4) were found to have correlation to each different stage of 
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cancer. Histone H2A, Calgizzarin  and Thymosin β4 were found to concentrate in the 
ductal carcinoma in situ region, invasive ductal carcinoma and stroma specifically. 
Nevertheless, since the imaging resolution of MALDI (~100µm) is bigger than the size of 
human cells, MALDI imaging has poor application ina single cell. It has been reported 
that the sensitivity of MALDI MS detection is typically on the level of Pmole and 
attomole sensitivity is also possbile (Nordhoff, Lehrach, and Gobom 2007). By coupling 
with microfluidics, MALDI is applicable for single cell protein analysis, which is used in 
this thesis. 
 
Figure 2-5: Application of MALDI imaging on a human breast carcinoma section. The 
scare bar shows the normalized amount of the proteins (red to white means 100% to 0%). 
H&E (Hematoxylin and eosin stain) stained section shows the areas of invasive ductal 
carcinoma, ductal carcinoma in situ (DCIS) and stroma. Protein histone H2A shows the 
highest signal in DCIS. Calgizzarin shows the highest intensity in inv asive ductal 
carcinoma and Thymosin β4 in stroma. Adapted from caprioli et al. (Seeley and Caprioli 
2008) 
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2.3 Quantitative Proteome Analysis by MALDI MS 
The goal of single cell proteome analysis is to demonstrate the changes of cell 
phenotypes induced by various environmental factors on the level of proteins. The 
proteome has been described as the quantitative image of a whole set of proteins in cells 
under defined conditions (Lottspeich 1999). Thus, acquisition of quantitative information 
about protein expression in single cells is a key subject in single cell proteome analysis. 
In MALDI MS analysis, cocrystallization of MALDI matrix and analyte is 
required for the desorption and ionization, but on the other hand is the major reason 
limiting quantitative analysis with MALDI MS. As the major issue of non-homogeneous 
distribution of the analyte originates from the cocrystallizaition process, strong detection 
intensities can be probed at some points whereas no analyte signals can be found at other 
points. This leads to poor reproducibility even at different locations on one sample spot. 
Besides, different molecules usually have different ionization efficiencies which are not 
predictable. The ionization efficiency of a specific molecule is dependent on the physical 
and chemical properties of the molecule itself (e.g interaction with MALDI matrix, 
chemical bonds, hydrophobicity, and volatility) and the environment (matrix effect). 
Additionally, secondary ion reactions after ionization and ion suppression effect in 
complex samples (e.g cell lysate) further hamper the use of MALDI MS for quantitative 
purposes. 
Despite these impeding factors, MALDI MS quantification can still be achieved 
via multiple strategies: (i) improvement of sample homogeneity by either modifying the 
matrix or solvent. (ii) isotope labeling (e.g: iTRAQ labeling, stable isotope labeling by 
amino acids in cell culture (SILAC) ) or (iii) an isotope labeled standard.  
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As discussed above, inhomogeneous distribution of sample in the sample-matrix 
co-crystals is a key factor limiting the quantitative MALDI analysis. Approaches for 
improving the sample homogeneity have been reported previously. One of the most 
commonly used methods is using ionic liquid matrices (ILM) as the MALDI matrix. 
Unlike the traditional MALDI matrix such as α-cyano-4-hydroxyl-cinnamic acid (CHCA) 
or sinapic acid, ionic liquid matrices form a highly viscous layer on the MALDI target 
plate (Armstrong et al. 2001). Thus, the sample can form a more homogenous distribution 
in this liquid layer. ILMs have been successfully applied for analyzing amino 
acids(Zabet-Moghaddam, Heinzle, and Tholey 2004), phospholipids (Li, Gross, and Hsu 
2005) and proteins (Armstrong et al. 2001). Relative quantification can be achieved in 
this analysis with applying suitable calibration standards. Moreover, it allows absolute 
quantification even without the use of the standards in a narrow dynamic range and under 
a specific matrix to analyte ratio (Tholey, Zabet-Moghaddam, and Heinzle 2006).  
Stable isotope labels introduced in a sample allow the quantitative MALDI MS 
analysis. The earliest possible way for introducing a stable isotope into proteins is by 
metabolic labeling. Nowadays, one popular strategy for incorporation of stable isotopes is 
SILAC. In SILAC, the cell medium often contains 
13
C6-arginine and 
13
C6-lysin. This can 
guarantee that all the products from tryptic digestion have at least one isotope labeled 
peptide, resulting in a mass increase over the non-labeled samples. Relative 
quantification is performed based on comparing the intensities of heavy species and light 
species. The advantage of this approach is to label proteins at the level of intact cells, 
which excludes all error sources coming from the mass spectrometric procedures 
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(Bantscheff et al. 2007). However, maintaining this system is expensive and time 
consuming. 
iTRAQ labeling is another method introducing stable isotopes into proteins.  
iTRAQ tags are a set of tags which have the same masses but different isotope 
compositions (Ross et al. 2004). The chemical structures of all tags are the same (drawn 
in Figure 2-6 A), eliminating the differences in ionization efficiencies. The complete 
molecule consists of a report group (N-methylpiperazine), a balance group (carbonyl), 
and a peptide-reactive group, a N-hydroxy succinimide). When the tag reacts with a 
peptide, the peptide-reactive group forms an amide linkage with all peptide amines 
(either N-terminal or amino group of side lysine). Figure 2-6 B shows an example of four 
iTRAQ tags with reporter groups ranging in mass from 114.1 to 117.1 Da while the 
balance groups range in mass from 28 to 31 Da.  Due to a constant molar mass, the 
peptides labeled with each of the tags have the same peak (m/Z [M+H]
+ 
145.1) in the MS 
spectrum. In the following MS/MS detection, the chemical bond linking the reporter 
group and the balance group breaks and the four reporter group ions appear as distinct 
masses (114-117 Da). The relative concentration of the peptides is thus obtained from the 
relative areas of the corresponding reporter ion peaks (Figure 2-6 C). Absolute 
quantification can be realized when the peptide amount is known in one sample. One 
potential disadvantage of this approach is that MS/MS analysis is a prerequisite, requiring 
more analysis time and additional instrumentation. But the ability to identify and quantify 
a protein without the need of peptide/protein sequence and complicated labeling process 
compared with in vivo labeling (SILAC) considerably outweighs this disadvantage. 
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Figure 2-6: A diagram showing the multiplexed iTRAQ tagging strategy. (A) Chemical 
structure of iTRAQ tags. (B) the overall mass of tag molecule is kept constant using 
different isotope enrichment with 13C, 15N and 18O atoms. (C) Illustration of isotopic 
tagging and quantification process. A kind of peptide from four samples is labeled with 
four different iTRAQ tags with four different reporter group masses. They are mixed and 
detected by MS/MS. The report groups can be distinguished in the MS/MS detection. 
Adapted from Ross e.t al. (Ross et al. 2004). 
 
Absolute quantification can also be achieved by applying internal standards (often 
known as isotope labeled synthetic standards). This method is now becoming more 
widely used and known as AQUA (absolute quantification of proteins). In this method, a 
known quantity of a stable isotope-labeled standard peptide is added to a protein digest. 
The comparison of internal standard signal and the sample peptide signal in MS spectrum 
allows the absolute quantification of the protein. This method has been used in clinics 
such as in the analysis and validation of potential biomarkers in a large quantity of 
  30 
clinical samples (Pan et al. 2005). Unlike the metabolic labeling and iTRAQ labeling 
which can provide quantitative information for large numbers of proteins at the same 
time, the addition of isotope labeled peptide usually focuses on one or a few particular 
target proteins in the sample (Pan et al. 2005). In addition, the choice of the synthetic 
peptide is important as there are likely several isobaric peptides present in the target 
protein mixture. Despite these limits, the advantages of this method such as fast analysis, 
not requiring tedious instrumentation and expensive materials are still attractive. 
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CHAPTER 3  
DIRECT DETECTION OF PEPTIDES AND PROTEINS REACHING SINGLE CELL 
SENSITIVITY 
3.1 Introduction 
It is well known that individual cells even having the same genotypes are different 
from each other (discussed in section 1.1). This kind of cellular heterogeneity cannot be 
revealed in the averaged bulk measurements. Understanding the heterogeneity between 
single cells is of enormous biological and clinical relevance. Single cell analysis gained a 
lot of interest in the past few years, capable of resolving the heterogeneity in single cells. 
However, new approaches with single cell sensitivity and label free detection are still 
needed.  
MALDI-TOF is a very powerful technique which has been widely used in the 
field of disease biomarker discovery due to its high sensitivity, speed and accuracy 
(Calligaris, Villard, and Lafitte 2011; Chao, Hansmeier, and Halden 2010; Petricoin et al. 
2002). However, in order to fully capitalize on these attributes, means of sample handling 
and manipulation techniques are needed that compatibly match the performance metrics 
of MALDI-TOF. This need is particularly acute when considering the analysis of a single 
cell where only an extremely low amount of analyte exists. Thus, technologies are 
necessary allowing sampling in the nano to pico liter range - ultimately reaching the 
volume of a single cell. Microfluidic devices have the potential to fulfill this requirement. 
It is suitable to handle picoliter single cell analyte with minimal dilutions. Moreover, 
proteome-relevant separation techniques such as immunoarrays, gel electrophoresis and 
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isoelectric focusing can be transferred to microfluidic devices, capable of reducing the 
sample complexity prior to MALDI-TOF analysis.  
In this chapter, I report first evidence that a combined microfluidic and mass 
spectrometric approach allows the detection of targeted proteins. From our results, the 
detection limit was found to be as few as 300 molecules at the peptide level, and ~ 10
6 
to 
10
7
 molecules at the protein level. Moreover, an immunoassay was integrated in the 
microfluidic device with subsequent MALDI-TOF-MS analysis. As it is known that for 
MALDI MS, lower molecular weight projectile has higher sputtering yield, narrower 
isotope distribution and thus higher detection sensitivity. Here, insulin was used as a 
target protein due to its low molecular weight compared with other proteins (>10kDa). 
This would result in an increased intensity in MALDI MS, making it a good model 
analyte as proof-of-principle. Based on the results of our study, we estimated detection 
limit on an anti-insulin immobilized surface (~0.05 mm
2
) of 10
6 
insulin molecules. This 
microfluidic-based method, therefore, approaches the sample-handling and sensitivity 
requirements for MS-based single-cell analysis of proteins and peptides. 
 
3.2 Materials and Methods 
3.2.1 Materials 
PDMS was purchased from Dow Corning Corporation. Acetonitrile, alpha-cyano-
4-hydroxycinnamic acid (α-CHCA), 3,5-dimethoxy-4-hydroxycinnamic acid, sinapic acid, 
recombinant human insulin, bovine serum albumin (BSA) and chicken anti-insulin 
antibody were obtained from Sigma-Aldrich. Alexa Fluor 488 chicken anti-rabbit IgG 
was purchased from Invitrogen. Peptide calibration mixture (bradykinin 
 
904.4681 m/Z 
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[M+H]
+
, angiotensin I 1296.6853 m/Z [M+H]
+
, qlu-fibrinopeptide [1570.6774 m/Z 
[M+H]
+
, neurotensin 1672.9175 m/Z [M+H]
+
) was purchased from AB SCIEX. Protein 
calibration mixture (insulin 5734.51 m/Z [M+H]
+
, ubiquitin 8565.76 m/Z [M+H]
+
, 
cytochrome C12360.97 m/Z [M+H]
+
, myoglobin 16952.30 m/Z [M+H]
+
) was obtained 
from Bruker Daltonics. ITO slides (100 ohm/sq) were purchased from NANOCS and Cr 
was obtained from SPI Supplies. Tridecafluoro-1, 1, 2, 2-tetra-trichlorosilane (TTTS) was 
obtained from Gelest. Isopropanol and acetone were obtained from VWR. SU-8 organic 
resin solution and SU-8 2075 developer were purchased from MicroChem. 
 
3.2.2 Microchip Fabrication 
PDMS microfluidic channels were fabricated via soft lithography using printed 
polymer masks (Fineline Imaging, USA), depicted as Figure 3-1. SU-8 2075 photoresist 
was spin coated onto a silicon wafer, which was then exposed to UV light with a mask 
aligner (System 3A, HTG, USA) for 32 seconds through the film photomask. After a post 
bake of 2 min at 65℃ and then 7 min at 95℃, the silicon wafer was immersed in SU-8 
developer for 4 minutes followed by 15 min hard bake at 150℃.  
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Figure 3-1: Workflow of photolithography. a) SU-8 negative photoresist is spin-coated on 
silicon wafer substrate. b) UV light exposure of SU-8 photoresist through a film mask to 
transfer the feature on the mask to the wafer. c) Mask removal and dissolvation of 
unexposed SU-8 photoresist in developing step. Exposed SU-8 photoresist remain on the 
wafer. 
The chip was made through the procedures shown in Figure 3-2. The resulting 
silicon master was then silanized under vacuum with TTTS. Afterwards, PDMS was 
poured over the master and cured at 80℃ for 4 h, removed from the master and cut in 
suitable pieces. Reservoir holes were punched manually with a biopsy punch (Fray 
Products, USA) to create the final PDMS manifolds. Then the PDMS manifolds were 
exposed to oxygen plasma with a Harrick plasma cleaner (PDC-001, Harrick, USA) for 
60 seconds under medium power settings. To ensure a reversible bonding between the 
PDMS and the ITO slides, the plasma treated PDMS slab was incubated in an oven at 80℃ 
before chip assembly. ITO coated glass slides (NANOCS, USA) were used as substrate 
for the PDMS manifolds. In order to allow better contrast for visual inspection during 
MALDI-TOF measurements the back of these slides was coated with a 25 nm thick layer 
of Cr with an Evaporator (308R, Cressington, UK). ITO slides were reused 5-8 times  
after washing with acetone and isopropanol. 
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Figure 3-2: Workflow of making a chip. a) PDMS is poured to the master wafer. b) Holes 
are punched at the ends of channels. c) The chip is assembled after plasma treatment of 
the PDMS slab. 
 
3.2.3 Protein Digestion 
BSA was digested as reported earlier (Chao, Hansmeier, and Halden 2010) with 
minor modification. In short, to 100 µg of BSA in 500 mM triethylammonium carbonate 
buffer (pH 8.5) was mixed with 1 µl of a 2% SDS stock solution and reduced with 2 µL 
of 0.5 M Tris(2-carboxyethyl)phosphine at 60℃ for 1 h. The resulting peptides were then 
alkylated by the addition of 2 µL of 200 mM methylmethanethiosulfonate in isopropanol 
and incubated for 15 min in the dark. Subsequently, 10 µL of a 1 mg/mL sequencing 
grade trypsin stock solution (Promega, USA) was added to the protein mixture and 
incubated at 37℃ overnight. The digest sample was cleaned with a C18 cleanup tip 
(Varian, USA) and the peptides were eluted with 0.1% TFA / 70% acetonitrile.  
 
3.2.4 Chip Loading and Manifold Removal 
Protein and peptide samples were diluted to different concentrations with water. 
Insulin was dissolved in 0.1 % v/v trifluoroacetic acid (TFA) and also diluted with water 
to the final concentration. 3 µL of the respective sample was mixed with either 3 µL of 
saturated α-CHCA in 60% v/v acetonitrile and 0.1% v/v TFA (for peptides) or 3 µL of a 
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saturated solution of sinapic acid in 40% v/v acetonitrile and 0.1% v/v TFA (for proteins). 
The mixture was then pipetted into the reservoir and the channels were filled by capillary 
action.  After 3 h drying at room temperature the PDMS manifold was peeled off and the 
ITO slide was used as a target for MALDI-TOF-MS. For immunocapture experiments 
with insulin, 5 µL of a saturated solution of sinapic acid in 30% v/v acetonitrile and 0.1% 
v/v TFA were filled in a reservoir and channels filled by capillary action. When the 
channel volume was completely dried (after ~3 h), the PDMS manifold was removed 
manually and the remaining ITO slide was used as target for MALDI-TOF-MS.  
 
3.2.5 MS Analysis 
MALDI-TOF-MS was performed using a Bruker Ultraflex III MALDI-TOF/TOF 
instrument. Peptide spectra were acquired in reflectron mode, whereas intact BSA and 
insulin were measured in linear mode. Calibration was performed with bradykinin, 
angiotensin, glu-fibrinopeptide and neurotensin in the low-MW range and with insulin, 
ubiquitin, cytochrome C and myoglobin for the higher MW-range. For a peptide 
spectrum 300 laser shots were summed while for intact BSA and insulin, 500 laser shots 
were summed. Variable laser intensities were used during each experiment to optimize 
the signal. The digested BSA-spectrum was searched against the Swissprot database 
('The Uniprot Consortium'  2012) with the MASCOT algorithm (Perkins et al. 1999) for 
identity validation. 
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3.2.6 Immobilization of IgG and Insulin Immunoassay 
Covalent IgG immobilization on ITO slides was performed as previously reported 
by Ng et al. (Ng et al. 2002). All protein solutions were prepared in phosphate buffer 
(20mM sodium phosphate dibasic, pH 8.0). Accordingly, 5 µL anti-insulin IgG solution 
(0.05mg/mL) was pipetted in the reservoir of an assembled chip and the microfluidic 
channels filled by capillary action. The chip was then kept in a humidity chamber at room 
temperature for 2 h. Subsequently, the protein solution was removed and the channel was 
washed three times with 20 mM phosphate buffer (pH=8.0) by vacuum action. This was 
followed by filling the channels with 1% (w/v) BSA solution by capillary action. The 
chip was then incubated in a humidity chamber at room temperature for 1h, the solution 
was removed and the channels were washed three times with phosphate buffer. Next, 5 
µL insulin solution (2 µM in 20mM phosphate buffer) was filled in the channels by 
capillary action followed by 1 h incubation in a humidity chamber at room temperature. 
Last, the insulin solution was removed and phosphate buffer was used to wash the 
channels thrice. After the phosphate buffer was removed, 5 µL of a saturated solution of 
sinapic acid in 40% v/v acetonitrile, 0.1% v/v TFA in water filled the channels by 
capillary action. The chip was subsequently allowed to dry and MALDI-TOF-MS 
performed.  
 
3.3 Results and Discussion 
3.3.1 Hyphenation of a Microfluidic Device with MALDI-TOF Instrument 
The goal of this study is to explore approaches with which an integrated device 
allowing immunocapture and subsequent mass-spectrometric quantification of proteins 
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with single-cell resolution can be realized. Our approach is based on a removable 
microfluidic platform on which analytes dissolved in suitable matrix solution are 
deposited in specific areas defined by the microfluidic platform, ultimately reaching the 
volume of a single cell. The top part of the microfluidic device consists of a PDMS 
manifold with a 0.5 cm long channel exhibiting a cross section of 50 µm x 60 µm 
fabricated by standard photo and soft-lithographic techniques. An ITO coated glass slide 
is used as reversible sealing during fluid handling steps and as the conductive MALDI 
target after matrix deposition. Moreover, this surface allows the covalent immobilization 
of immunocapture proteins and is fully transparent enabling the microscopic analysis of 
all sample and pre-treatment steps.  
To ensure a reversible bonding between the PDMS and the ITO slides, PDMS 
manifolds are exposed to oxygen plasma for 60 sec under medium power settings while 
the ITO slide is not treated. During the oxygen plasma treatment, the surface of the 
PDMS is oxidized and hydroxyl groups were generated, forming a strong covalent bond 
with an ITO slide. The plasma treated PDMS slab is incubated in an oven at 80 ℃ for 
half an hour before chip assembly. This possibly help reduce the strength of the bond due 
to the hydrophobic recovery of PDMS surface. In this way, reversible assembling can be 
achieved. To find out this best protocol enabling reversible binding and capillary action, 
multiple conditions were attempted (data not shown).  
The PDMS platform is removed after all liquid handling steps, with the remaining 
analyte-matrix co-crystallized on the spatially defined ITO surface. The microfluidic 
manifold thereby created micrometer sized patterns that were analyzed with MALDI-
TOF-MS. This approach is schematically depicted in Figure 3-3. 
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Figure 3-3: a) Schematic workflow of microfluidic-based MALDI-TOF-MS analysis. 
Cross section of a channel manifold containing several microchannels is fabricated using 
the elastomer PDMS (Note: only one channels cross sections is shown). A microfluidic 
channel is filled with a mixture containing either peptides or proteins and a suitable 
MALDI matrix. After the cocrystallization of the sample and matrix, the top PDMS 
manifold is removed and the remaining crystals are probed by MALDI-TOF-MS 
subsequently. b) Schematic of the 3D peel-off procedure for three channels. c) 
Photographs of the assembled microchip (top) and showing deposited co-crystals on the 
ITO surface (bottom) after peel-off (Note: the backside of the ITO slide is coated with a 
25 nm thick layer of Cr). 
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3.3.2 Detection and Identification of Peptides and Proteins 
Using optimized assembly conditions (as reported in section 3.3.1) we studied the 
sensitivity of the proposed combined MALDI MS and microfluidic technique for the 
detection and identification of proteins and peptides. To assess the detection limit for 
proteins, we used BSA, BSA digest and insulin, whereas the peptide calibration mixture 
was used as a peptide sample. 
Samples were premixed with matrix solution before loaded into the microdevice. 
After they co-crystallized at ambient temperature, areas both resulting from the reservoir 
and channel regions defined by the microfluidic manifold were analyzed. Since highly 
purified calibration peptides generally provide excellent S/N ratios we first investigated 
the detection limit with a dilution series of a peptide mixture consisting of angiotensin, 
bradykinin, neurotensin and Glu-fibrinopeptide within our microdevice. We measured 
within the reservoir as well as regions defined by the microfluidic manifold (Figure 3-4 a) 
and b)). The lowest limit of detection was achieved for angiotensin with a loaded 
concentration of 1.3 pM and a S/N of 7.7 from a microchannel region (Figure 3-4 b)). 
The resulting S/N ratio at this concentration in the reservoir was 2.7. The other peptides 
could still be detected at concentrations of 130 pM with S/N ranging from 1.6 to 10.8 in 
the reservoir and from 3.2 to 14.0 in microchannels (data not shown). 
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Figure 3-4: MALDI-TOF-MS spectra of peptides and protein digest obtained from the 
combined microfluidic and MALDI-MS approach: Angiotensin spectra obtained from a) 
reservoir and b) microchannel at a concentration of 1.3 pM (resulting in ~300 molecules 
probed). Spectra of a trypsin BSA digest obtained from c) reservoir and d) microchannel 
at a concentration of 6.0×10-9M corresponding to 1.1×106 molecules. 
 
Since the analytes are distributed evenly along the length of the channel and 
throughout the reservoirs, we estimated the number of molecules detectable in any given 
channel segment by assuming a laser diameter of 100 µm hitting the surface. Thus, a 
surface area fo 50 µm x 100 µm was tested corresponding to a volume of 300 pL (note 
that the cross section of the microchannel is 50 µm x 60 µm). We further assume that the 
complete amount of proteins or peptides in this given volume contributed to the final 
signal. Using angiotensin as example, we calculate that 3.9×10
-22
 mol (0.4 zmol) 
angiotensin were detected. This corresponds to only ~ 300 molecules. This indicates that 
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a peptide could be detected in copy numbers relevant for single cell analyses (Beck et al. 
2011). 
For proteins such as BSA a higher detection limit is expected. Accordingly, we 
were able to detect BSA with S/N of 2.5 with an initial concentration of 5.0×10
-7
 M from 
surface regions defined by a microfluidic channel (see Figure 3-5 a) and b)). For insulin, 
we could obtain a spectrum with S/N of 4.3 with concentration of 5×10
-8
M in a 
microfluidic channel (see Figure 3-5 c) and d)). Using the above mentioned 
considerations, this corresponds to about 9×10
7
 BSA molecules or 9×10
6
 insulin 
molecules contributing to the displayed spectrum.  
These detection limits are at the higher abundance limit of protein content suitable 
for single-cell- based assays. Note that Beck et al. (Beck et al. 2011) recently reported 
protein abundance spanning seven orders of magnitude within a range of 10.000 to 20 
million in single human cells. Considering the large range in abundance we decided to 
test whether a protein digest would improve the protein detection limit. As an additional 
benefit this approach also allows the identification of the protein using the resulting 
fragment peptide spectra in a peptide mass fingerprinting approach, which provides more 
information on the measured protein than the average mass alone. 
Thus, we loaded varying concentrations of trypsin-digested BSA with matrix 
solution into the microdevice and performed MALDI-TOF-MS (Figure 3-4 c) and d)). 
The number of detectable peaks declined with decreasing concentration of the digest 
within the channel. However, even at a concentration of 6×10
-9
 M, 7 peaks were detected 
with S/N ratios ranging from 2.6 to 17.3 from a region defined by the microchannel. 
Moreover, the identified peptides covered 18% of the protein and allowed the 
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identification of BSA with a significant score of 117 in UniprotKB human protein 
database . Assuming the same laser beam diameter and channel volume probed as 
mentioned above and with a BSA concentration of 6.0×10
-9
M, we estimate 1.8×10
-19
 mol 
corresponding to 1.1×10
6
 molecules. These results are encouraging and indicate that in 
principle even without pre-concentration the detection of as few as 3.1×10
-22
 mol 
peptides and 1.8×10
-19
mol proteins is possible. 
 
Figure 3-5: MALDI-TOF-MS spectra of proteins obtained from the combined 
microfluidic and MALDI-MS approach: Intact BSA spectra obtained from c) reservoir 
and d) microchannel at a concentration of 5.0*10
-7
 M corresponding to ~9*10
7
 molcules 
probed. Intact insulin spectra obtained from a) reservoir and b) channel at a concentration 
of 5*10
-8
M corresponding to ~ 9*10
6
 molecules probed. 
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3.3.3 Affinity Capture and MS Detection in a Microfluidic Channel 
After establishing a method to detect proteins and peptides with MALDI-TOF-
MS in a microfluidic system, we developed a simple method to allow specific 
immunoreaction of analytes of interest within the microfluidic device. For this purpose, 
we chose anti-insulin IgG to capture and subsequently detect human insulin within from 
surface areas previously defined by the microfluidic manifold.   
 Covalent IgG immobilization on ITO slides was performed as previously 
reported (Ng et al. 2002). To ensure optimal coverage of the ITO surface with IgGs, we 
determined the saturation concentration with fluorescently labelled IgGs. The saturated 
concentration of IgG for the immobilization on ITO slides was determined by 
fluorescence microscopy. Fluor 488 chicken anti-rabbit IgG was dissolved in water and 
diluted in a series of concentrations ranging from 2×10
-4 
mg/mL to 0.1mg/mL. 5 μL of 
IgG solution with varying concentrations were pipetted into different reservoirs on an 
ITO surface and incubated in a humidity chamber at room temperature for 2 h. These 
reservoirs were subsequently washed with 20 mM phosphate buffer for three times. 
Fluorescence intensity of each reservoir was recorded on a fluorescence microscope 
(Olympus IX71, Olympus, USA) using a CCD camera (Photometrics, AZ). The intensity 
of each reservoir was obtained by averaging the intensity of five images and the result is 
shown in Figure 3-6. At a concentration of 0.05 mg/mL we observed no further increase 
in fluorescence indicating the saturation of surface coverage. We thus employed this 
concentration for all further IgG immobilization steps. 
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Figure 3-6: Fluorescence intensity of fluorescently labeled IgG for various incubation 
concentrations immobilized on ITO slides. 
 
In order to ascertain specificity in our immunoassay we first performed a series of 
experiments on the ITO surface without the PDMS manifold. We treated the ITO surface 
with a 5 μL droplet of an anti-insulin IgG at a concentration of 0.05 mg/mL. To block 
free binding sites on the ITO slide we then incubated the slides with a 10 mg/mL BSA 
solution. After washing with phosphate buffer, we incubated the slide with a 2 µM 
insulin solution for 1 h to allow binding to the antibodies. Following removal of unbound 
insulin through an additional washing step, we added matrix solution and performed 
MALDI-TOF-MS.  
The resulting MS spectra allowed the detection of insulin peaks with an average 
m/Z of 5808.05 corresponding to the expected mass of insulin with [M+H
+
] ([5808.57]
+
), 
see Figure 3-7 a). In addition, we found additional peaks with an average m/Z of 8536.45 
that we were not able to assign to any of the used components. Subsequent analyses 
revealed that it is most likely a contaminant found in the commercial BSA batch. Due to 
its m/Z we were not able to detect the contaminant in the assay for the intact BSA, nor in 
the digest. 
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Figure 3-7: MALDI-TOF-MS analysis of anti-insulin immunoassays: a) Representative 
spectrum obtained with anti-insulin IgG from a reservoir, b) representative spectrum 
obtained with non-binding IgG from a reservoir, c) Representative spectrum obtained 
with anti-insulin IgG from single probed spot defined by the microchannel, d) 
Representative spectrum obtained with non-binding IgG from single probed spot defined 
by the microchannel. 
 
As a control for the specificity of the binding reaction we performed the same 
experiment but replaced the anti-insulin antibody with IgG directed against rabbit-IgG 
(see Figure 3-7 b)). From 9 independent experiments we were not able to detect spectra 
corresponding to insulin, indicating that the binding of insulin occurred specifically to the 
corresponding IgG and blocking steps of the ITO surface were sufficient. 
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Figure 3-8: Schematics of the Insulin immunoassay performed on an ITO surface within 
a microfluidic channel: a) with insulin binding specific anti-insulin IgG, b) with non-
binding IgG. 
 
Next, we performed the same assay in the complete microdevice (shown in Figure 
3-8). The same concentrations and incubation times as for the slide assay were used and 
after the final washing step matrix solution was introduced by capillary action. The 
resulting mass spectra are shown in Figure 3-7 c) and Figure 3-7 d). For the insulin-
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Correspondingly, the insulin signal did not appear for the non-specific anti-body assay. 
Finally, we estimated the number of molecules of immobilized anti-insulin IgG per 
surface area and deducted the number of molecules of insulin probed by this assay. As we 
performed IgG incubations at the saturation concentration, we estimate that a monolayer 
of IgG molecules was formed. This monolayer is probed by a laser of ~100 µm diameter. 
With an estimated area of 5 nm×10 nm (50 nm
2
) one immobilized IgG molecule covers, 
we conclude that roughly 10
8
 IgG molecules were probed by the MALDI laser on the 
area defined as the intersection of laser spot and ITO surface defined by the microfluidic 
channel. We further estimate that only 5 % of the immobilized IgG molecules are active 
and that each IgG binds one insulin molecule. This results in roughly 5×10
6
 molecules 
that were probed in this assay in a microchannel. 
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Our study thus demonstrated that affinity capture of insulin on a single anti-
insulin IgG coated surface layer is possible. We emphasize that this is the first example – 
to the best of our knowledge - realized on an ITO surface and with an immunoassay 
specific for insulin. Although other immunocapture assays on gold surfaces have been 
demonstrated with various analytes by others (Kim et al. 2012) and us (Nelson et al. 1999; 
Nelson and Krone 1999; Nelson, Nedelkov, and Tubbs 2000), this work furthermore 
demonstrates the coupling of microfluidic pre-treatment steps and consequently a high 
spatial resolution (~50µm). Moreover, the number of molecules probed with our 
approach originating from a surface area of of 0.05 mm
2
 approaches the detection 
sensitivity of proteins for single cell analysis. We emphasize on the fact that the probed 
area can easily be decreased by reduction of the microfluidic pattern. Using standard 
photolithography, such patterns can be created as small as a few µm and the possibility of 
nanostructuring could further reduces this limit. Coupling integrated fluidic handling 
tools such as valves and pumps additionally provide the advantage of automizing and 
parallelizing this technology for high throughput applications coupled to minute sample 
amounts down to single cell. 
 
3.4 Section Conclusions 
In this work we investigated a suitable condition to create a microfluidic device 
that allows direct coupling of immunocapture with following MALDI-MS analysis with a 
spatial resolution of 50 µm. The key aspect of this approach is that the microfluidic 
manifold can be removed readily from the MADLI-MS target after immunocapture for 
subsequent analysis. Detection sensitivity for peptides and proteins has been 
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demonstrated with this approach. We were able to infer the detection of as low as 300 
molecules (0.4 zmol) of the peptide angiotensin. As expected from the generally higher 
detection sensitivity for MALDI-MS of proteins we obtained mass spectra originating 
from defined areas in a microfluidic channel amounting in roughly 108 molecules of 
BSA and 10
7
 insulin. Not unexpectedly, the mass fingerprinting of a BSA-digest resulted 
in two orders of magnitude better sensitivity. Besides, a simple insulin immunoassays on 
ITO surfaces within areas of ~0.05 mm
2
 was successfully coupled in this microfluidic 
device and the MALDI MS Spectra indicated that the insulin was specifically captured by 
anti-insulin on the ITO surfaced confined by microfluidic channels. More importantly, 
the observed detection limits are close to the requirements of analyzing proteins and 
peptides originating from single or few cells. We envision that this inexpensive 
microfluidic system holds the potential to perform bioanalytical investigations with single 
cell resolution. 
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CHAPTER 4  
A MICROFLUIDIC PLATFORM FOR PROTEIN IDENTIFICATION AND PROTEIN 
QUANTIFICATION 
4.1 Introduction 
Gain of quantitative information about protein expression in single cells is 
essential to understand biological processes such as those involved in cell apoptosis, 
cancer, biomarker discovery, disease diagnostics, pathology or therapy. Most of the 
quantification approaches in single cell analysis are based on fluorescence measurements 
which are limited due to restricted range of fluorescent dyes. Analysis of cellular 
compounds in single cells using MALDI MS has been reported suitable for 
characterization of proteins in single cells such as single mammal cells (Li, Golding, and 
Whittal 1996) and single yeast cell (Amantonico et al. 2008). However, quantitative 
information is not provided and lack of proper compartmentalization approach leads to 
extremely low throughput.  
In this chapter, I report on our efforts to develop a quantitative mass spectrometric 
approach combined with microfluidic technology for protein identification and 
quantification. Analysis multiplexing was realized by a series of chambers and valves in a 
microfluidic platform, ensuring a set of defined wells for absolute quantification of 
targeted proteins. To this aim, isotopic labeling strategies were applied by employing 
iTRAQ-labels to an on-chip protocol. Simultaneous protein digestion and labeling was 
performed on the microfluidic platform, making the labeling strategy compatible with all 
necessary manipulation steps on-chip, including the matrix delivery for MALDI-TOF 
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analysis.  We demonstrated this approach with the apoptosis related protein Bcl-2 and 
quantitatively assess the number of Bcl-2 molecules detected. 
 
4.2 Materials and Methods 
4.2.1 Materials 
iTRAQ reagents multi-plex kit was obtained from AB Sciex (USA). Trypsin was 
obtained from Promega Corporation (USA). Isopropanol and acetone were from VWR 
(USA). SU-8 2075 photoresist and SU-8 developer were from MicroChem (USA). 
PDMS was purchased from Dow Corning Corporation (USA). Acetonitrile, alpha-cyano-
4-hydroxycinnamic acid (α-CHCA), Bcl-2 active human, Anti-Bcl-2 antibody and bovine 
serum albumin (BSA) were from Sigma-Aldrich (USA). Alexa Fluor 488 chicken anti-
rabbit IgG was purchased from Invitrogen (USA). Peptide calibration mixture 
(angiotensin II  1046.5418 m/Z [M+H]
+
, angiotensin I 1296.6848 m/Z [M+H]+, 
substance P [1347.7354 m/Z [M+H]
+
, bombesin 1619.8223 m/Z [M+H]
+
, ACTH clip 1-
17 2093.0862 m/Z [M+H]
+
, ACTH clip 18-39 2465.1983 m/Z [M+H]+, somtostatin-28 
3147.4710 m/Z [M+H]
+
) was purchased from Bruker Daltonics Inc (USA). ITO slides 
(100 ohm/sq) were obtained from NANOCS and Cr was obtained from SPI Supplies 
(USA). Tridecafluoro-1, 1, 2, 2-tetra-trichlorosilane (TTTS) was purchased from Gelest 
(USA).  
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4.2.2 Microchip Fabrication 
All polydimethylsiloxane (PDMS) channels were fabricated via soft lithography 
using printed polymer masks. For proof of principle, three straight channels were used for 
Bcl-2 immunoassay, on-chip digestion and iTRAQ tagging experiments. The chip was 
assembled reversibly with the method reported previously (Yang et al. 2012).  
Standard procedures of PDMS-based multi-layer soft lithography were also used 
to fabricate microfluidic devices with normally closed valves (called ladder-like device in 
the following text) (Unger et al. 2000). The structure of the ladder-like device is shown in 
Figure 4-1 a. This two layer device included a fluidic layer (filled with colors) composed 
of ten separated wells and a control layer (red) with microchannels actuated by negative 
pressure. PDMS microchannels on both layers were molded from patterns of 43 µm thick 
negative photoresist SU-8 2075. The photoresist was spin-coated onto a silicon wafer 
followed by a soft baking procedure for 3 min at 65℃, and 9 min at 95℃.  The wafer was 
exposed to UV light for 45 seconds through the film photomask with a mask aligner 
(System 3A, HTG, USA). After a post baking for 2 min at 65℃ and 7 min at 95℃, the 
silicon wafer was soaked in SU-8 developer for 5 min followed by 20 min hard baking at 
150℃. The silicon master was then silanized with TTTS to avoid adhesion between 
PDMS and the silicon wafer. For the control layer, 48 g of a 6:1 w/w ratio of PDMS to 
curing agent solution was poured onto the silicon master. For the fluidic layer, 16 g of a 
15:1 w/w ratio of PDMS to curing agent solution was spin-coated on the silicon master 
for 30 sec at 1300 rpm, yielding a thickness of 75 µm thin layer (Zhang and Ferguson 
2004). Both layers were cured at 65℃ for about 40 min. After curing, the control layer 
was cut from the silicon master and manually aligned with the fluidic layer which was 
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still on the silicon wafer using a stereomicroscope (FB-220U, Olympus, USA). The 
whole device was cured again at 65℃ overnight for tight bonding. Afterwards, the two-
layer PDMS mold was peeled off from the silicon master and holes were punched 
manually with a 2 mm biopsy punch (Fray Products, USA).  
The PDMS manifold was treated with oxygen plasma in a Harrick plasma cleaner 
(PDC-001, Harrick, USA) for 90 sec under medium power settings before chip assembly. 
ITO coated glass slides (100ohm/sq, NANOCS, USA) were used as the substrate. The 
backside of ITO slides was coated with a 25 nm thick layer of Cr with an Evaporator 
(308R, Cressington, UK), allowing visual inspection during MALDI-TOF measurements. 
ITO slides were reused 5-8 times after cleaning with acetone and isopropanol. 
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Figure 4-1: a) Top view of the ladder-like microfluidic device with pneumatic valves. 
Red lines indicate the channels in the actuation layer and rectangles the position of the 
pneumatic valves. Channels filled with brown and yellow color indicate the fluidic layer 
containing the incubation and mixing wells (not to scale). Right: bright field image of 
two chambers (at left and right of image). b) Feature of the flow channel when valve B is 
open and valve A and C are closed. Five regions (I-V) are available for MALDI-TOF-MS 
after the PDMS manifold is peeled off. Each region is composed of two opposed wells 
with each well (filled with green color) amounting in a volume of ~15 nL. c) Cross-
sectional views of the pneumatic valve in closed (left) and open (right) state. d) Optical 
images of the valve in closed and open state. e) Workflow of on-chip protein 
quantification by iTRAQ tags. 
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4.2.3 Bcl-2 Immunoassay, Digestion and iTRAQ Tagging 
Proof-of-principle experiments for the iTRAQ labeling and digestion procedure 
were performed in a straight channel with a dimensions of 50 µm×60 µm×1 cm. Anti-
Bcl-2 antibody was immobilized covalently on ITO slides as reported by Ng et al.(Ng et 
al. 2002) Protein solutions were prepared in phosphate buffer (20 mM sodium phosphate 
dibasic) if not stated otherwise. 5 µL anti-Bcl-2 IgG solution (0.05 mg/mL) was pipetted 
into the reservoir and capillary flow filled the channel within a few seconds. After 2 h 
incubation in a humidity chamber at room temperature, IgG solution was removed and 
the microchannel was washed three times with 20 mM phosphate buffer by vacuum 
suction. Then, the channel was filled with 1%(w/v) BSA and incubated for an hour in 
order to block the unspecific binding positions. The BSA was removed followed by 
washing with phosphate buffer for three times. Subsequently, 5 µL Bcl-2 solution (0.037 
mg/mL) was filled in the channels by capillary action. After 1 h incubation in a humidity 
chamber at room temperature, Bcl-2 solution was removed by vacuum and the channel 
was washed three times by 100 mM ammonium bicarbonate buffer. Afterwards, the 
channel was filled with 5 µL trypsin solution (0.1 µg/µL, dissolved in 100 mM 
ammonium bicarbonate buffer) and incubated in a humidity chamber at 37°C overnight. 
When the channel was completely dried, the channels were filled with 5 µL matrix 
solution (saturated α-cyano-4-hydroxycinnamic acid (CHCA) in 40% v/v acetonitrile, 0.1% 
v/v TFA in water solution) by capillary action. After the matrix solution in the channel 
was completely crystallized, the PDMS mold was peeled off and the remaining ITO slide 
with crystals was used as target for MALDI-TOF-MS.  
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In the tagging experiment, initial steps were the same as above except adding 
trypsin solution mixed with one iTRAQ tag. After the Bcl-2 solution was removed and 
the channel was washed three times by iTRAQ dissolution buffer (iTRAQ™ reagent kit, 
AB SCIEX, USA), a mixture composed of 4 µL trypsin solution (0.1mg/mL) and 5 µL 
iTRAQ tag solution (obtained by adding 70 μL ethanol to one tube of 117 tag) filled the 
channel simultaneously followed by 4 h incubation in a humidity chamber at 37°C. When 
the channel was completely dried, 5 µL CHCA matrix solution was added and the same 
steps were repeated for the MALDI measurement. 
 
4.2.4 Bcl-2 Quantification in the Ladder-Like Device 
In preparation of internal standard sample, Bcl-2 was digested and labeled with 
one iTRAQ tag off chip. First, Bcl-2 was cleaned by a centrifugal filter (Amicon-0.5mL 
3K, Millipore, USA) to get rid of glycerol which would affect the digestion. 
Concentration of cleaned Bcl-2 solution was determined by Bradford protein assay 
(Bradford assay, Bio-Rad, USA). 2 µL cleaned Bcl-2 was mixed with 8 µL iTRAQ 
dissolution buffer, 2 µL trypsin solution (0.1mg/mL) and 8 µL iTRAQ tag solution 
(obtained by adding 70  µL ethanol to one tube of 114 tag). This solution was incubated 
at 37°C overnight and used as the internal standard for on-chip Bcl-2 quantification. 
Bcl-2 quantification experiment on chip was carried out with pneumatic valves 
integrated (Figure 4-1 a). Negative pressure of ~100 mbar was applied through a 
MFCSTM-EZ system (Fluigent Inc, USA) to open and close the valves (Figure 4-1 c and 
d) for fluidic manipulation steps. Stainless steel pins (Idex corporation, USA) were cut to 
1.5 cm each for connecting the chip with the MFCSTM-EZ system. The workflow is 
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shown in Figure 4-1 e. First, Bcl-2 immunoassay, digestion and iTRAQ tagging steps 
were repeated in the fluidic channel I. In this step, valve A was open while valve B and C 
were closed for all of chip loading steps. Valve A, B and C were closed for all of the 
incubation steps. Next, in fluidic channel II, valve C was open while valve A and B were 
closed. 5 µL internal standard solution filled the fluidic channel II by negative pressure. 
Afterwards, valve A and C were closed while valve B was open and closed repeatedly for 
2 min in order to mix the sample and the internal standard solution. The chip was placed 
at ambient atmosphere overnight until channels were completely dried. Last, valve B was 
closed while valve A and C were open. 5 µL of CHCA matrix solution filled the fluidic 
channel I and II. After the solution in the channel was completely crystallized, the two-
layer PDMS manifold was peeled off and MALDI-TOF-MS was performed on the ITO 
slide with crystals. 
 
4.2.5 MS Analysis 
MALDI-TOF-MS was performed using a Bruker Ultraflex III MALDI-TOF/TOF 
instrument. Peptide spectra were acquired in reflectron mode and 1000 laser shots were 
summed. Calibration was performed with angiotensin II, angiotensin I, substance P, 
bombesin, ACTH clip 1-17, ACTH clip 18-39, somtostatin 28. The digested Bcl-2 
spectrum was searched with the MASCOT algorithm for identity validation. Experiments 
with iTRAQ tags were performed by using MALDI-TOF MS/MS. MS/MS spectra were 
acquired with 1000 shots for each examined spot. The whole detection region (as shown 
in Figure 4-1 b) was manually scanned in order to capture signal from all crystals in the 
well area. Thus, around 35 spots were examined in each detection region. The position of 
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each well in the device was identified via the crystal rim formed by co-crystallization of 
MALDI matrix and sample with the camera in the MALDI TOF instrument. The 
spectrum of Bcl-2 digest was searched against the Swissprot database with the MASCOT 
algorithm for identity validation. Due to a narrow isotope distribution of the peak, the 
peak area and peak height are nearly the same in this analysis. The peak area was chosen 
here for quantification purposes. Peak areas of report groups in MS/MS spectra were 
analyzed using OriginPro software. 
 
4.3 Results and Discussion 
This section is divided into three parts. First, a novel microfluidic device was 
described for quantification of proteins combined with MALDI-MS analysis. Second, we 
report on the adaptation of enzymatic digestion and iTRAQ labeling necessary for the 
combined microfluidic-MS approach. In the last part, we report the quantitative detection 
of the apoptosis marker Bcl-2 with the combined microfluidic-MS approach and discuss 
the impact for future single cell analysis. 
 
4.3.1 Chip Fabrication and Valve Actuation 
The aim of our study is to achieve protein affinity capture, protein identification 
and quantification by a combined microfluidic and mass spectrometric method. 
Ultimately, this method should allow studies on small cell ensembles or single cells. To 
this aim, we developed a reversible bonding procedure between an ITO substrate and a 
PDMS manifold allowing the PDMS to be peeled off and thus exposing matrix crystals 
on the ITO substrate for MALDI-TOF analysis. Improvement of microfluidic devices 
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(Figure 4-1 a) over our precious study (Yang et al. 2012) was realized by integration of 
membrane valves actuated by negative pressure. This approach has the advantage that 
first, regions formed by closed valves have a fixed surface area and volume, allowing for 
absolute quantification; second, the novel approach allows adding matrix solution in a 
control channel preventing dilution or washing out sample when internal standard was 
added; third, it allows active mixing of an internal standard with the sample by actuating 
valves. A PDMS membrane valve (Figure 4-1 c) was selected due to its compatibility 
with the necessary reversible binding condition.  Positive pressure actuated valves (Unger 
et al. 2000) were not considered to avoid fluid leaking due to the reversible bonding of 
PDMS manifold and ITO substrate (data not shown).  
Figure 4-1 c shows the cross sectional view of this valve. This valve includes a 
control layer with ~3 mm height and a fluidic layer with ~100 µm height. Both the 
control channel which is in the control layer and the fluidic channel which is in the fluidic 
layer resulted in a thickness of 43 µm. The thin membrane, also serving as the ceiling of 
the fluidic channel was ~30 µm thick (Zhang, Ferguson, and Tatic-Lucic 2004) and the 
valve stop attached to the thin membrane had a height of 43 µm to stop the flow in the 
fluidic channel. To actuate the valve, negative pressure was applied in the control channel 
to lift the valve stop. A key factor determining the actuation pressure was the adhesion 
forces between the valve stop and the ITO surface (Mohan et al. 2011). Optical 
microscopy was employed to verify the open and closed states of the valve (Figure 4-1 d). 
The oval-shaped area indicated by blue arrows in the state indicated that the membrane 
was lifted off and touched the roof of the control channel.  
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4.3.2 Affinity Capture and Identification of Bcl-2 in Microfluidic Channels 
In order to adapt the proposed methodology to a larger protein with suitable 
sensitivity, we first developed an enzymatic digestion step succeeding an affinity capture 
step on-chip (see Figure 4-2). Herein, a larger protein Bcl-2 was chosen for this approach. 
Bcl-2 is known to play a critical role in apoptosis regulation (Czabotar et al. 2014). In 
order to test the incubation and digestion procedure, we first carried out experiments in a 
straight microfluidic channel without integrated valves. It was previously demonstrated 
that biomolecules including antibodies and antigens, attached covalently, spontaneously, 
and robustly onto the ITO surface (Ng et al. 2002). The saturation concentration for 
antibodies on ITO was determined with fluorescently labeled IgGs as previously reported 
(Yang et al. 2012). We followed this strategy and the ITO surface was treated within the 
microchannel with an anti-Bcl-2 antibody at a saturated concentration of 0.05mg/mL. A 
BSA treatment step followed in order to block the non specific binding sites. After the 
BSA was removed by washing with phosphate buffer, the channel was filled with Bcl-2 
solution and then incubated to allow the binding with anti-Bcl-2 antibody. After renewed 
washing, trypsin was added and the channel was incubated in a humidity chamber at 
37°C overnight for complete protein digestion. Last, matrix solution was added to 
facilitate MALDI-TOF-MS. The detailed incubation and washing steps for this protocol 
are outlined in the Section 4.2.3. 
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Figure 4-2: Schematics of the Bcl-2 immunoassay and tryptic digestion performed on an 
ITO surface within a microfluidic channel: a) with insulin binding specific anti-insulin 
IgG, b) with non-binding IgG (anti-rabbit IgG). 
 
As shown in Figure 4-3 a,  the MALDI-TOF spectrum in which six peptide peaks 
(1210.6 m/Z [M+H]
+
, 1950.8 m/Z [M+H]
+
, 1994.8 m/Z [M+H]
+
, 2295.1 m/Z [M+H]
+
, 
2886.6 m/Z [M+H]
+
, 3596.8 m/Z [M+H]
+
) labeled with red triangles were identified 
corresponding to expected masses from a tryptic Bcl-2 digest (See Table 4-1). These 
peaks showed a sequence coverage of 50% with a significance score of 104 in a 
SwissProt data base search successfully identifying the protein Bcl-2. Additional peaks 
from BSA, anti-Bcl-2 IgG and trypsin fragments were also found in the spectra.  
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Figure 4-3: a-b) MALDI-TOF-MS analysis of an anti-Bcl-2 immunoassay followed by 
Bcl-2 on-chip tryptic digestion: a) Representative spectrum obtained with anti-Bcl-2 IgG. 
b) Similar to a) but with non-binding IgG. c-d) MALDI-TOF-MS analysis employing an 
immunoassay on chip followed by iTRAQ labeling during digestion: c) simultaneous on-
chip tryptic digestion and iTRAQ labeling after an anti-Bcl-2 immunoassay. d) MS/MS 
spectrum of parent mass ([M+H]+ m/Z=1355.7) selected from the spectrum shown in c) 
(inset: low mass range spectrum showing the report ion used for quantification). 
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Mass In the 
spectrum 
Peptide 
Position 
Peptide Sequence 
1210.6 130-139 FATVVEELFR 
1950.8 111-127 DFAEMSSQLHLTPFTAR 
1994.8 130-146 FATVVEELFRDGVNWGR 
2295.1 165-183 EMSPLVDNIALWMTEYLNR 
2286.6 69-98 TSPLQTPAAPGAAAGPALSPVPPVVHLTLR 
3596.8 27-63 GYEWDAGDVGAAPPGAAPAPGIFSSQPGHTPHPAASR 
Table 4-1:  Identification of peaks from 1.4 µM in the spectrum 
A control experiment was performed employing the same protocol but using 
chicken anti-rabbit IgG to verify the specificity of the immunoassay. As shown in Figure 
4-3 b, m/Z peaks corresponding to the Bcl-2 digestion could not be found in the spectra, 
indicating that Bcl-2 was specifically captured by the binding IgG, but not in the control 
experiment. Moreover, BSA blocking and washing steps on the ITO surface were 
sufficient to remove nonspecific binding of Bcl-2.  
This MS-based on chip immunoassay can now be compared with previous work. 
Our previous study demonstrated that the affinity capture of insulin on a single anti-
insulin IgG coated ITO surface layer was achieved by detection of intact insulin (Yang et 
al. 2012). Here, with the additional on-chip digestion approach, we were able to detect 
the larger 26 kDa protein Bcl-2. We thus extended the combined microchip-MS approach 
to the identification of proteins on the level of peptides formed by digestion of target 
proteins via peptide mass fingerprinting. Our previous results showed that detection of a 
protein digest would improve the protein detection limit by two orders of magnitude 
(Yang et al. 2012). This is another benefit of performing on-chip enzymatic digestion 
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allowing the analysis of larger proteins in small amounts of cells even down to a single 
cell. 
 
4.3.3 iTRAQ Tagging of Bcl-2 
Due to lower limit of peptide detection, we further quantitatively investigated the 
number of Bcl-2 proteins detected employing the microchip digestion procedure. In our 
previous approach (Yang et al. 2012) without enzymatic digestion, we estimated that 
roughly 5×10
6
 molecules were probed. This amount is in the range of high abundant 
proteins in single cells (~10
6
 protein molecules) (Xie et al. 2008) however is limited to 
small proteins and peptides, lacked the possibility of multiplexing and is potentially 
subject to washing and dilution losses. Here, we improved our previous approach by 
adapting the protocol for two iTRAQ tags allowing for true quantification. In this 
approach, the on-chip immunoassay was followed by a digestion step in which peptides 
were labeled with one iTRAQ tag. A protein digest with a known concentration as an 
internal standard was labeled with the second iTRAQ tag and mixed with the first digest 
on chip for quantification, which was achieved based on the peak area ratio of these two 
tags after MS/MS analysis.  
A typical iTRAQ protocol as suggested by the supplier is not possible in this chip-
assay, since two independent steps of digestion and iTRAQ labeling will not allow 
quantitative results. Renewed filling steps would simply wash sample out of the 
microfluidic channel. Thus, in order to avoid this problem, we developed a protocol 
allowing for simultaneous digestion and labeling in one step (see section 4.2.3). An 
experiment of simultaneous digestion and iTRAQ labeling of captured Bcl-2 digest was 
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carried out in a straight channel to verify that the iTRAQ labeling process could be 
applied in the proposed microfluidic platform (as outlined in Figure 4-1e). Instead of 
adding the trypsin solution alone, we added a mixture composed of trypsin and iTRAQ 
tag simultaneously, followed by an incubation at 37°C. MALDI matrix was added and 
the co-crystallized sample was analyzed by MALDI MS. 
The resulting MS spectrum (Figure 4-3 c) shows four Bcl-2 digest peaks (1210.6 
m/Z [M+H]
+
, 1950.8 m/Z [M+H]
+
,  2886.6 m/Z [M+H]
+
, 3596.8 m/Z [M+H]
+
) shifted to 
larger masses (1355.7 m/Z [M+H]
+
, 2095.9 m/Z [M+H]
+
,  3031.7 m/Z [M+H]
+
, 3741.9 
m/Z [M+H]
+
) due to addition of the iTRAQ tag (145.1 m/Z [M+H]
+
). The corresponding 
MS/MS spectrum of one selected mass 1355.7 m/Z [M+H]
+
 is shown in Figure 4-3 d and 
the reporter group 117.1 m/Z [M+H]
+ 
of the tag is apparently observed. Figure 4-3 c and 
Figure 4-3 d indicate that the simultaneous digestion and iTRAQ labeling was 
successfully developed.  
To examine whether iTRAQ labeling approach is proper for single cell analysis, 
we tested the lowest concentration of Bcl-2 which could be quantified by iTRAQ strategy 
was determined.  1.4×10-5M of Bcl-2 was digested and separately labeled with 114 tag 
and 117 tag by using the procedures described in the above section. The stock 
concentration of tagged Bcl-2 digest was 1.4×10-6 M. A dilution series of this solution 
(either 114 tagged or 117 tagged) was made from 1.4×10-6 M to 1.4×10-9 M. The two 
tags were mixed in 1:1 ratio. Results are shown below (Table 4-2). We further note that 
the typical concentration of protein in the cell lysate is ~1 µM calculated via the copy 
number (10
6
) of a high abundant protein in about 1 pL cell volume. The iTRAQ strategy 
is successful down to a concentration of 14 nM, suitable for quantifying the proteins in 
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single cells. We further tested the sensitivity of the method in regards to the Bcl-2 
concentrations and the iTRAQ labeling ratio (see Appendix A 1-2), which are in good 
agreement with previous studies on iTRAQ labeling strategies (Wiese et al. 2007). 
Concentration 114/117 ratio 
1.4×10
-6
M 0.75 ±0.26 
1.4×10
-7
M 1.08±0.44 
1.4×10
-8
M 1.21±0.46 
1.4×10
-9
M No peak identified 
Table 4-2: Dilution series for iTRAQ quantification on Bcl-2. The theoretical ratio of two 
tags was 1:1.  
 
4.3.4 Quantification of Bcl-2 in the Ladder-Like Device 
The next challenge consisted in reproducible and metered delivery of the second 
iTRAQ label for the intended quantification. For this purpose, a microfluidic platform 
was developed capable of on-chip iTRAQ tagging of target protein captured in an 
immunoassay and delivering reference iTRAQ label in known amounts with integrated 
mixing of the sample and reference peptide. This procedure is outlined schematically in 
Figure 4-1 e. In fluidic channel I (Figure 4-1 a), Bcl-2 immunoassay, digestion and 
iTRAQ tagging steps were performed when valves A are open and valves B and C were 
closed. In the opposed fluidic channel II (Figure 4-1 a), an internal standard solution 
originating from 1.4×10
-7
 M reference digest was loaded when valve C was open and 
valve A and B were closed. Subsequently, the contents in opposite wells were mixed by 
actuating valve B while valve A and C were closed.   
This procedure allows for mixing of the iTRAQ peptides from the chip digest 
with a reference digest containing the reference protein at a known concentration labeled 
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with the second iTRAQ tag. Five regions could be manipulated simultaneously allowing 
for five parallel experiments. The valves formed defined surface area and volume in each 
well allowing for absolute quantification. Repeatedly actuating valve B allowed active 
mixing of an internal standard in fluidic channel II with the sample in fluidic channel I. 
Thorough mixing of these two solutions was required in this protocol since Bcl-2 was 
quantified based on the peak area ratio of two tags from two fluidic channels.  
To assure that the digested sample and the internal standard were mixed 
sufficiently and the signal was homogeneous in one detection area, a control experiment 
was performed with a fluorophore in the above ladder-like device (Figure 4-1 a). We 
repeated the mixing procedure in our quantification experiment by using 100mM sodium 
fluorescein. Fluidic channel I was filled with sodium fluorescein while the opposing 
fluidic channel II was filled with water when valve B was closed. Then, valve B was 
repeatedly opened and closed to mix dye and water. Averaged fluorescence intensities for 
each well were calculated at each time point. We found that fluorescence intensities on 
both fluidic wells reached the same value at 2 min indicating the homogeneity of the 
fluorescence in one detection region (see Figure 4-4). 
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Figure 4-4: Averaged fluorescence intensity in one well in fluidic channel I and the 
opposed well in fluidic channel II when valve B is repeatedly opened and closed. Errors 
are the standard deviations of fluorescence intensities recorded in each well (insert: 
fluorescent images showing the opposite wells before mixing (left) and 2 min after 
mixing (right). The brighter area in the middle of the right image indicates the region 
where the valve is open). 
 
Next, this improved platform was tested in the complete MALDI MS assay. For 
this purpose, MALDI matrix was loaded in both fluidic channel I and fluidic channel II 
after affinity capture of Bcl-2, digestion, iTRAQ tagging and mixing with the reference 
iTRAQ tag was accomplished. Finally, the PDMS manifold was removed after co-
crystallization on chip and MALDI-TOF analysis was performed. The parent mass 
(1355.7 m/Z [M+H]+) was selected to perform MS/MS analysis and one example 
spectrum is shown in Figure 4-5, showing both the sample and reference iTRAQ mass. 
The MS/MS spectrum in Figure 4-5 indicates that this approach was successfully applied 
for quantitative MALDI MS analysis. Moreover, five regions shown in Figure 4-1 b (I-V) 
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from four chips were analyzed with an average peak area ratio of 2.9 (±0.45) 
corresponding to the ratio of 114.1 m/Z [M+H]+ to 117.1 m/Z [M+H]+. We note that the 
addition of matrix to channels I and II can potentially lead to dissolution of peptides 
during the filling process and a peptide concentration gradient along the wells. Assessing 
each well in all devices tested has however not revealed a gradient of the peptide 
intensities (data not shown). The matrix introduction procedure was necessary to assure 
matrix/sample co-crystallization, since filling of the matrix through channel I alone did 
not result in crystals. Further improvement of the valving system can improve this 
situation as well as a careful study of the matrix composition.   
The quantitative analysis of the peak ratios now allows the calculation of the 
number of Bcl-2 molecules detected. One well as shown in Figure 4-1 b comprises a 
volume of ~15 nL. Thus, with an internal standard sample at a concentration of  
1.4×10
-7
 M, we conclude that ~ 4.4×10
8
 Bcl-2 molecules were captured in each well.  
Moreover, one well results in a surface area of (3.5±0.2)×10
5
 µm
2
 from which we 
calculate a surface coverage of Bcl-2 of (2.1±0.4)×10
-21
mol/µm
2
. In this calculation, we 
assume that labeling efficiencies of both reactions are the same since the same iTRAQ 
procedures are applied for the sample and the internal standard. Thus, the labeling 
efficiency can be neglected in the ratiometric determination of peptide concentrations. 
Previously, we estimated roughly 5×10
6
 molecules that were probed in a similar 
assay with insulin where the laser laser shot area amounted in 5×10
4
 µm
2
 in a 
microchannel (Yang et al. 2012). This resulted in a surface coverage of 1.7×10
-21
mol/µm
2 
which is comparable to the result obtained by the here presented iTRAQ quantification.  
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Figure 4-5: Representative MS/MS spectrum of the two iTRAQ labels from a Bcl-2 on-
chip quantification with an anti-Bcl-2 immunoassay. MS/MS spectrum was assayed from   
parent mass [M+H]+ m/Z=1355.7 (insert: low mass range showing the report ions used 
for quantification). 
 
It is commonly assumed that copy numbers of proteins in single cells vary from 
low abundant (several ten copies) to high abundant (a few million copies) (Xie et al. 
2008). Assuming 10
6
 protein molecules of one kind, the current surface area of the 
detection well could capture protein from a maximum of ~440 cells. Note that a well with 
area of  ~800 µm
2 
would be required for detecting high abundant proteins (10
6
 molecules) 
from one single cell.  It is well known that using standard photolithography technology, 
the area of a well can be made as small as 800 µm
2
. The here presented approach 
advantageously performs all incubation steps in a defined volume – the well on the chip – 
avoiding the problem of dilution.  
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4.4 Section Conclusions 
We investigated suitable experimental conditions for simultaneous tryptic 
digestion and iTRAQ labeling for on-chip protein identification and quantification. 
Moreover, we integrated this workflow in a microfluidic device capable of five 
simultaneous assays followed by MALDI MS/MS analysis. The new device allowed 
assay steps to be performed independently with subsequent on chip delivery of iTRAQ 
labels for absolute protein quantification. This approach allowed the analysis of the 
number of molecules detected in each individual well through iTRAQ labeling. This 
study indicates that in order to reach single cell sensitivity, i.e. assessing a protein copy 
number of 10
6
 molecules from a single cell, a microfluidic well downscaled to a 
minimum surface area of  ~800 µm
2
 is required. The presented microfluidic approach 
could thus be adapted to capture one cell per well and would allow the quantification of 
high abundant proteins from single cells. The downscaling of the well geometry will 
further increase the throughput whereas the current soft lithography and fluidic mixing 
approaches are suited for a larger scale integration. Our future work is dedicated to the 
integration of cell loading and cell lysis steps with the here presented approach and we 
envision that it can be applied to quantitative proteomics in single cells in the future. 
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CHAPTER 5  
IMPROVEMENT OF ABSOLUTE PROTEIN QUANTIFICATION BY AN 
ISOTOPICALLY LABLED PEPTIDE 
5.1 Introduction 
 Accurate measurement of a specific protein amount that a cell produces is 
essential for investigating basic biological processes. And the assessment of this 
quantitative information will ultimately lead to significant progresses in drug design and 
development, cancer diagnostics and treatment. Single cell proteomic analysis has 
attracted more and more interest in the past few decades (Janicki et al. 2004). However, 
there is an urgent need for technologies that permit the direct quantification of proteins 
from single cells. 
Traditional quantitative assays measuring relative or absolute protein amounts 
such as western blots or immunoblots typically start with the separation of large amount 
of cells (Renart, Reiser, and Stark 1979; Verbeek et al. 1996). The detection limits are 
often picomole at the best, making them limited for single cell analysis. The conventional 
method for single cell protein analysis is fluorescence-based approaches due to the high 
sensitivity. For example, FACS (fluorescence-activated cell sorting) uses fluorescently 
labeled antibodies to label the target proteins from single cells. Currently there are a 
maximum of 18 proteins from single cells that can be measured and quantified 
simultaneously by multi-color flow cytometry (Freer and Rindi 2013). Despite of these 
recent developments, fluorescence-based approaches reply on molecular probes that need 
to be preselected. And the species that can be detected by the fluorescence analysis are 
also limited due to the limited range of fluorescent dyes. 
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We reported a novel microfluidic device for absolute quantification of proteins by 
using two iTRAQ tags previously (discussed in chapter 4). This method could potentially 
be used for single cell protein analysis. However, there are some drawbacks for this 
approach. MS/MS spectra must be obtained for distinguishing iTRAQ tags, requiring 
more analysis time and additional instrumentation. Besides, technical issues of applying 
this iTRAQ technology to our approach still exist. In the iTRAQ quantification 
experiment, mixing the MALDI matrix with the iTRAQ internal standard beforehand 
would not lead to co-crystallization. Consequently, the MALDI matrix solution filled 
after the sample was dried in both fluidic channels. The renewed filling of MALDI 
matrix would lead to dissolution of peptides and sample washing out.  In this chapter, we 
improve our quantification approach by applying an isotope labeled peptide as the 
internal standard. Adding the isotope labeled peptide with the MALDI matrix can avoid 
the problem of peptides dissolution and transport. Thus five completely independent 
experiments can be performed in parallel in our device. Without the need of MS/MS 
analysis, quantification by using isotope labeled peptide can simplify the quantification 
process and holds the potential to quantify Bcl-2 from single cells. 
 
5.2 Materials and Methods 
5.2.1 Materials 
PDMS was purchased from Dow Corning Corporation (USA). Acetonitrile, 
alpha-cyano-4-hydroxycinnamic acid (α-CHCA), Bcl-2 active human was from Sigma-
Aldrich (USA). Peptide calibration mixture (angiotensin II  1046.5418 m/Z [M+H]
+
, 
angiotensin I 1296.6848 m/Z [M+H]
+
, substance P [1347.7354 m/Z [M+H]
+
, bombesin 
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1619.8223 m/Z [M+H]
+
, ACTH clip 1-17 2093.0862 m/Z [M+H]
+
, ACTH clip 18-39 
2465.1983 m/Z [M+H]
+
, somtostatin-28 3147.4710 m/Z [M+H]
+
) were purchased from 
Bruker Daltonics Inc (USA). Trypsin was obtained from Promega Corporation (USA). 
ITO slides (100 ohm/sq) were obtained from NANOCS and Cr was obtained from SPI 
Supplies (USA). Tridecafluoro-1, 1, 2, 2-tetra-trichlorosilane (TTTS) was purchased 
from Gelest (USA). Isopropanol and acetone were from VWR (USA). SU-8 2075 
photoresist and SU-8 developer were from MicroChem (USA). Isotope labeled peptide 
(FATVVEELeu(d10)FR) was from GenScript USA Inc. 
 
5.2.2 Digestion Efficiency Test of Bcl-2 in Solution 
5µL of 1.4×10
-5
 M was diluted with 45 µL of 50 mM NH4HCO3 and then was 
mixed with 10 µL of 0.1 µg/µL trypsin (dissolved in 50 mM NH4HCO3). The mixture 
was divided into five parts which were incubated separately for 4 h, 6 h, 12 h, 24 h, 36 h 
at 37 ℃. Subsequently, 1.5 µL of 1.1× 10-5 M internal standard peptide was added to each 
sample and the vials were vortexed. 5 µL matrix solution (saturated α-cyano-4-
hydroxycinnamic acid (CHCA) in 40% v/v acetonitrile, 0.1% v/v TFA in water solution) 
was added. The samples were pipetted and spotted on an ITO slide followed by MALDI-
TOF-MS analysis. 
 
5.2.3 Absolute Protein Quantification by Using an Isotope Labeled Peptide 
The Bcl-2 quantification experiment by using isotope labeled peptide as an 
internal standard was carried out in the ladder-like device (Figure 4-1a). First, Bcl-2 
immunoassay and digestion steps were repeated in fluidic channel I as described in 
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Section 4.2.3. In this step, valve A was open while B and C were closed for all chip 
loading steps.  Valve A, B and C were closed for all of the incubation steps. Next, 5 µL 
of 100nM isotope labeled peptide with a sequence of FATVVEELeud10FR was mixed 
with 5 µL matrix solution. This mixture filled the fluidic channel II by applying negative 
pressure when valve A and B were closed and valve C was open. Afterwards, valve A 
and C were closed while valve B was open and closed repeatedly for 2 min in order to 
mix the sample and the internal standard solution. The chip was placed in air overnight at 
room temperature until channels were completely dried. After the solution in the channel 
was completely crystallized, the two-layer PDMS manifold was peeled off and MALDI-
TOF-MS was performed on the ITO slide with crystals. 
 
5.3 Results and Discussion 
In our approach, the peptide with sequence of FATVVEELFR and m/Z [M+H]
+
 
1210.6 is chosen as the sample peptide in the Bcl-2 digest since this peptide usually has 
the highest S/N in Bcl-2 digest MS spectrum An isotope labeled peptide with the same 
sequence as the sample peptide but containing stable isotopes is used as an internal 
standard (reference peptide). In comparison to the sample peptide which originates from 
Bcl-2 digest, the reference peptide with sequence of FATVVEELeu(d10)FR has a 10 Da 
shift m/Z [M+H
+
] 1220.6 due to deuterium labeling. Therefore, the MS analysis allows 
the detection of both the sample peptide from the Bcl-2 digest and the isotope labeled 
peptide.  By comparison of the peak area intensities between the reference peptide and 
the sample peptide, the number of the sample peptide from the Bcl-2 digest is determined.  
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5.3.1 Solution Digestion Efficiency  
Our ultimate goal is to apply this quantification method in single cell protein 
analysis which requires high sensitivity detection. To find out the optimum incubation 
time in the digestion protocol, the efficiency of in solution digestion was tested. Bcl-2 
with known amount (1.4×10
-11 
mol) was digested by trypsin in a vial for various 
incubation times (4h, 6h, 12h, 24h, 36h). 1.7× 10
-11 
mol of reference peptide was added in 
the digest for quantification purpose. One example spectrum is shown in Figure 5-1. The 
average peak area ratio of peak [M+H]
+
 m/Z 1220.6 and peak [M+H]
+
 m/Z 1210.6 was 
1.6±0.12 obtained from three repeated trials. With the amount of 1.7× 10
-11 
mol reference 
peptide, the number of the sample peptide was calculated as (1.1±0.08) × 10
-11 
mol. Since 
the starting Bcl-2 amount was 1.4×10
-11 
mol, we calculated that the digestion efficiency 
was 78.6% in this case. By using the same approach, the digestion efficiencies for 4 h, 6 
h, 12 h, 24 h, 36 h were calculated accordingly. As shown in Figure 5-2, the digestion 
efficiency reached the maximum  at 12 h incubation. Thus, for all digestion experiments, 
12h incubation was used and 78.6% digestion efficiency was used for correlation of the 
sample peptide and the corresponding Bcl-2 amount. 
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Figure 5-1: Representative MS spectrum of Bcl-2 in solution digestion with 12h 
incubation. (insert: zoom in picture of the red rectangular region showing the sample 
peptide and reference peptide peaks used for quantification). 
 
 
Figure 5-2: Digestion efficiencies for various incubation times ranging from 4h to 36h. 
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5.3.2 Bcl-2 Quantification On-chip by Using an Isotope Labeled Peptide 
In our previous study with  iTRAQ tags for quantification (Section 4.3.4 ), one 
problem we encountered was that the MALDI matrix could not be added together with 
the iTRAQ internal standard from the opposite channel as the sample and MALDI matrix 
would not cocrystallize. Thus, we filled the MALDI matrix from both channel I and 
channel II after the whole chip was completely dried. This procedure might lead to 
dissolution of peptides during the filling process and a peptide concentration gradient 
along the wells. To further verify the quantification results and avoid the problem of not 
being able to cocrystalize, a quantification experiment was performed in the ladder-like 
device (Figure 4-1a) by applying an isotope labeled peptide as the internal standard. 
 Similarly, Bcl-2 affinity capture and digestion were performed in fluidic channel 
I. In comparison to the iTRAQ quantification experiment, the major difference was that 
the MALDI matrix was mixed with internal standard beforehand. This mixture loaded in 
fluidic channel II by applying negative pressure and was then mixed with contents in 
channel I by actuating valve B. In this way, the internal standard loading step and 
MALDI matrix loading step were combined without the need of filling the matrix 
separately to the channel where samples were dried. Therefore compared with the iTRAQ 
quantification experiment, the problem of peptides dissolution and transport along the 
five detected regions can be avoided. Last, after co-crystallization, the PDMS manifold 
was removed and subsequent MS analysis was performed. The peaks of sample peptide 
and reference peptide were distinguished in MS spectrum and the peak area ratio of two 
peptides indicated their concentration ratio.  
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One example MS spectrum from these five regions is shown in Figure 5-3. Both 
the sample peptide (m/Z [M+H]
+ 
1210.6) and the isotope labeled peptide (m/Z [M+H]
+ 
1220.6) are shown in the spectrum (red arrows), allowing the quantitative analysis of Bcl-
2 captured on chip. Five regions shown in Figure 4-1b (I-V) from four chips were 
analyzed with an average peak area ratio of 17.7± 1.19 corresponding to the ratio of 
1210.6 m/Z [M+H]
+ 
to
 
1220.6m/Z [M+H]
+
. As the isotope labeled peptide concentration 
was 100 nM and the volume of a well was ~15 nL, we calculated that around 8.5×10
-17
 
mol of Bcl-2 sample peptide was in each well. Thus, the number of Bcl-2 captured in 
each well was ~7.0×10
7 
mol corrected with the 78.6% digestion efficiency.  
 
Figure 5-3: Representative MS spectrum of sample peptide from Bcl-2 digest and the 
internal standard peptide. 
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Based on quantification by using iTRAQ tags discussed in chapter 4, 4.4×10
8
 Bcl-
2 molecules are detected in each well. By using an isotope labeled peptide, we conclude 
that 7.0×10
7 
is detected in each well which is around six times lower than the detected 
Bcl-2 number obtained from iTRAQ quantification approach.  
Errors might exist in both quantification approaches. For iTRAQ quantification 
experiment, possible errors are related to the labeling efficiency and digestion efficiency. 
The prerequisite of using iTRAQ labeled peptide as the internal standard is that the ways 
of labeling sample and internal standard should be kept the same. In spite of applying the 
same simultaneous digestion and labeling protocol for both sample and internal standard, 
the labeling and digestion efficiencies on chip (for the sample) and in solution (for the 
reference peptide) might be different.  
For quantification by an isotope labeled peptide, a possible error related to the 
determination of digestion efficiency might also exist. Digestion efficiency is calculated 
for solution digestion whereas the Bcl-2 is captured and digested on the surface in the 
quantification experiment. In the calculation of the absolute number of Bcl-2 molecules, 
the solution digestion efficiency is used to correlate the sample peptide with the 
corresponding Bcl-2. It has been shown that the enzymatic cleavage of an antigen-
antibody complex is reduced, especially at the region where the protein contacts with the 
antibody (Doucette, Craft, and Li 2003).  Considering a smaller digestion efficiency for 
proteins bound to the antibodies on chip, the corresponding Bcl-2 amount calculated will 
be larger than  7.0×10
7 
molecules per well. 
Besides, the variation of Bcl-2 peptide intensities along five detection regions was 
examined for both approaches by looking at the relative standard deviation of signals in 
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different detection regions. For quantification by isotope labeled peptide, the relative 
standard deviation (RSD) of five detection regions was found to be 7% while 20% RSD 
is determined in iTRAQ experiments. As discussed in Section 4.3.4, the MALDI matrix 
must be loaded separately with internal standard in the iTRAQ approach since mixing the 
MALDI matrix with the internal standard beforehand could not lead to sample co-
crystallization. The renewed MALDI matrix loading step could possibly result in the 
dissolution of peptides and transport of the samples along the channel. Thus, the iTRAQ 
tag quantification expectedly has a higher variation of peptide intensities along the five 
detection regions. 
 
5.4 Section Conclusions 
In this chapter, we investigated the optimum condition for Bcl-2 tryptic digestion 
and found that 12h incubation could result in best digestion efficiency. 76.8% digestion 
efficiency for 12h digestion incubation was determined by using an isotope labeled 
peptide as the internal standard. The quantitative analysis of proteins was improved by 
applying an isotope labeled peptide for on-chip Bcl-2 quantification.  The internal 
standard (isotope labeled peptide) could be introduced with MALDI matrix at one time 
from fluidic channel II, which would not lead to dissolution of peptides during the matrix 
filling process and thus keep the five detection regions separate. This can further enable a 
smaller variation of peptide intensities in five detection regions compared to the iTRAQ 
quantification experiment. Our study based on an isotope labeled peptide indicated that 
7.0×10
7 
Bcl-2 molecules were detected in each well. In order to assess a protein copy 
number of one million molecules from a single cell, the current device is required to be 
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further downscaled. Our future work is to couple this protein analysis method with cell 
loading and cell lysis on chip. We anticipate that this approach can be applied to quantify 
cancer biomarkers from single cells in the future. 
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CHAPTER 6  
DETECTION AND QUANTIFICATION OF BCL-2 IN CANCER CELLS 
6.1 Introduction  
Single cancer cell detection provides a new powerful tool in understanding cancer 
evolution and the role of rare cells in the cancer development which is difficult to address 
with bulk tumor measurements. This new tool is especially useful in cancer early 
detection and monitoring. Cancer cells undergo dramatic changes compared with normal 
cells including and protein expression level (Weinberg 2013). The protein express level 
change can serve as an indicator of the cancerous cells. These indicators are termed 
biomarkers (Jain 2010). Biomarker discovery is a hot topic in the biomedical research 
area. Significant differences in single cells were found for the concentration of various 
proteins (Wu and Singh 2012; Ullal et al. 2014). This strong protein expression diversity 
within a cell population is associated with the diagnosis of various diseases such as 
cancer (Shapiro et al. 1995; Verbeek et al. 1996). Therefore, understanding the protein 
expression level in single cells is of high clinical and biological interest.  
Spectroscopy approaches can give a snapshot of the cell content but is often 
incapable of detecting specific proteins. Analysis of cellular contents at the single-cell 
level using MALDI MS has been reported (Rubakhin and Sweedler 2008) . However, it 
lacks an efficient way for multiplexed analysis, resulting in low throughput. Thus, high 
throughput analysis with MALDI MS detection is needed. Cell isolation and the 
subsequent cell lysis based on microfluidics have been well established for single cell 
analysis such as the droplet microfluidics (Mazutis et al. 2013), mechanical microtraps 
(Stratz et al. 2014) and microwells (Xie et al. 2015). In addition, microfluidics can 
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provide high throughput analysis and an efficient way to integrate multiple sample 
manipulations steps, which is convenient for subsequent detection. 
We achieved multiplexed and label free single cell protein analysis by using the 
ladder-like microfluidic device developed before (discussed in Chapter 4 and 5). Our 
previous work showed that protein identification and quantification could be realized in 
this device with MALDI-TOF MS detection.  In this chapter, this work is extended to 
analyze proteins in single cancer cells. Several functions including single cell loading and 
lysis, sample pretreatment prior to MALDI MS can be integrated in this device. Bcl-2 is a 
key protein involved in cell apoptosis (Czabotar et al. 2014) and it has been reported that 
Bcl-2 is over expressed in various types of malignant cells compared to normal cells 
(Kandouz et al. 1996). It has an important biological and clinical relevance. Thus Bcl-2 is 
chosen as our target protein for proof of principle. We believe that our approach can be 
applied to analyze other proteins in single cells and thus provides a powerful way for 
single-cell proteomics. 
 
6.2 Materials and Methods 
6.2.1 Materials 
PDMS was purchased from Dow Corning Corporation (USA). Acetonitrile, 
alpha-cyano-4-hydroxycinnamic acid (α-CHCA), Bcl-2 active human, Anti-Bcl-2 
antibody and bovine serum albumin (BSA), bovine insulin were from Sigma-Aldrich 
(USA). Dulbecco’s phosphate-buffered saline (DPBS) buffer and the Hausser scientific 
hemocytometer were purchased from Thermo Fisher Scientific (USA). Peptide 
calibration mixture (angiotensin II 
 
1046.5418 m/Z [M+H]
+
, angiotensin I 1296.6848 m/Z 
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[M+H]
+
, substance P [1347.7354 m/Z [M+H]
+
, bombesin 1619.8223 m/Z [M+H]
+
, 
ACTH clip 1-17 2093.0862 m/Z [M+H]
+
, ACTH clip 18-39 2465.1983 m/Z [M+H]
+
, 
somtostatin-28 3147.4710 m/Z [M+H]
+
) was purchased from Bruker Daltonics Inc 
(USA). ITO slides (100 ohm/sq) were obtained from NANOCS and Cr was obtained 
from SPI Supplies (USA). Tridecafluoro-1, 1, 2, 2-tetra-trichlorosilane (TTTS) was 
purchased from Gelest (USA). Isopropanol and acetone were from VWR (USA). SU-8 
2075 photoresist and SU-8 developer were from MicroChem (USA). Isotope labeled 
peptide (FATVVEELeu(d10)FR) was from GenScript USA Inc. MCF-7 cells, Eagle’s 
Minimum Essential Medium (EMEM), fetal bovine serum were obtained from ATCC 
(USA). 
 
6.2.2 Cell Lysis 
MCF-7 cells were cultured in a solution of Eagle’s Minimum Essential Medium 
(EMEM) (ATCC, USA) with L-glutamine, 10% fetal bovine and 0.01 mg/mL of bovine 
insulin at 37°C for five days. The flask with cells was placed in the sterilized fume hood. 
The EMEM medium was removed by vacuum from the flask which was then washed by 
7mL Dulbecco’s phosphate-buffered saline (DPBS) buffer (Thermal Fisher Scientific, 
USA). Then the DPBS buffer (thermal fisher scientific, USA) was sucked out and 2mL of 
cell stripper solution was added for stripping the cells from the surface of the petri dish. 
The flask was placed in 37 °C incubator for 10 min. Then 3 mL MCF-7 medium was 
added to the flask. The solution in the flask was transferred to a tube and centrifuged. The 
cell pellet was used for the following experiments. 
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The cell pellet was frozen in a -20°C freezer for 5 min and then thawed at 37°C 
for 5 min. This freezing and thawing cycle was repeated for 3 times to lyse the cells. Next, 
the glass hemocytometer and the coverslip were cleaned with alcohol before use. The 
coverslip was moistened with water and affixed to the hemocytometer. Last, 100 µL cell 
suspension was gently vortexed and applied to the hemocytometer. Live cells from five 
selected rectangular areas were counted before lysis and after lysis under the microscope 
(IX71, Olympus, US). 
 
6.2.3 Detection of Spiked Bcl-2 in MCF-7 Cell Lysate 
Bcl-2 was spiked and detected in MCF-7 cells with concentrations over five 
orders of magnitude from 5 cells/µL to 5×10
4
 cells/µL to understand the influence of the 
sample complexity on Bcl-2 detection. MCF-7 cells were stripped from a Petri-dish and 
resuspended in 50 mM NH4HCO3 (digestion buffer).  Cells were lysed by three freezing 
and thawing cycles and a dilution series was made ranging from 5 cells/µL to 5×10
4
 
cells/µL to 5 cells/µL. For 140nM Bcl-2 sample, 1 µL of 1.4×10
-6
 M  Bcl-2 was added 
while for 14nM Bcl-2 sample, 1 µL of 1.4×10
-7
 M  Bcl-2 was added to 8 µL cell lysate 
with various concentrations. 1 µL of 0.2 µg/µL trypsin were added in all sample solutions 
subsequently. All samples were probed by MALDI-TOF after 12 h incubation at 37°C. 
 
6.2.4 Coupling Cell Loading, Lysis with Protein Affinity Capture, Identification and 
Quantification on Chip 
This experiment was also performed in the device shown in Figure 6-1a. Likewise, 
in all procedures, valve A was open while valve B and C were closed for all chip loading 
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steps. Valve A, B and C were closed for all incubation steps unless otherwise stated. First, 
channel I was filled with anti-Bcl-2 IgG solution (0.05mg/mL) through capillary flow. 
After 2 h incubation, IgG solution was removed and the microchannel was washed three 
times with DPBS buffer. 1% BSA solution filled the channel I followed by 1 h incubation. 
BSA solution was removed by vacuum and the channel was washed again by DPBS 
buffer. Next, cell solution with Bcl-2 spiked in (3000 cells/µL in DPBS buffer) was 
loaded in fluidic channel I. Here, spiked Bcl-2 concentration was 10
-8
M. The whole chip 
was repeatedly placed in the -20°C freezer for 3 min and 37°C oven for 3 min three times 
to lyse the cells. Subsequently, the chip was incubated for 1h at the room temperature and 
the solution was removed by vacuum. 0.1 µg/µL trypsin dissolved in 50 mM NH4HCO3 
filled channel I and the chip was incubated at 37°C for 12 h. A mixture composed of 
MALDI matrix and the isotope labeled peptide (10
-8
M) was loaded in fluidic channel II. 
Solutions from fluidic channel I and channel II were mixed when valve A and C were 
closed while B was repeatedly opened and closed. Last, after channel I and channel II 
were completely dried to induce cocrystallization, the PDMS slab was removed. The 
sample on the ITO substrate was probed by MALDI MS. This experiment was repeated 
with three chips. 
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Figure 6-1: Structure of ladder-like device. a) Top view of the ladder-like device (Red 
line: control channels; Brown and Yellow filling: fluidic channels). b) Feature of the flow 
channel when valve B was open and valve A, C were closed.  Five regions (I-V) were 
available for MALD-TOF MS detection after PDMS slab was peeled off. 
 
6.3 Results and Discussion 
6.3.1 MCF-7 Cell Lysis 
Since we aim in detecting the proteins produced in single cells, a proper cell lysis 
approach is needed to release the proteins from the cells before the subsequent protein 
measurements. The lysis of single cells for downstream lab-on-a-chip devices can be 
achieved by a variety of means such as optical (Rau et al. 2004; Rau et al. 2006), acoustic 
(Zhang and Jin 2004), mechanical (Di Carlo, Jeong, and Lee 2003), electrical (Lu et al. 
2006) or chemical lysis (Berezovski, Mak, and Krylov 2007; Ocvirk et al. 2004). Each 
has their strength and weakness. Selection of the appropriate lysis method is highly 
dependent on the particulars of the downstream analysis of cell lysate. In our approach, 
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after the cell lysis, proteins are expected to be captured by antibodies and subsequently 
digested by trypsin before MALDI MS detection. Chemical lysis is often performed with 
highly concentrated detergents which will interfere the downstream MALDI MS analysis. 
Electrical cell lysis has always been used widely in lab-on-a chip devices or in capillaries 
(Han et al. 2003; Nashimoto et al. 2007; Lu et al. 2006; Gabriel and Teissie 1999). 
However, in our case, potentials applied to a microchannel with buffer over ITO slides 
destroyed the ITO coating on the surface (data not shown). That might be due to 
electrochemical reactions occurring on the conductive ITO surface. In addition, the 
proteins from the cell lysate retain their ability to are preferred to be native which can 
actively bind with antibodies immobilized on the surface. Freezing and thawing has been 
reported to not denature the proteins as much as other methods (detergent-based, acoustic, 
mechanical lysis) (Qi, Sun, and Xiong 2015). Besides, it does not need complex and 
expensive instrumentation. Therefore, rapid freezing and thawing cycles were used as the 
cell lysis method in our work.  
Our goal is to analyze proteins at the single cell level after they are released from 
single cells due to cell lysis. In order to release target proteins completely from single 
cells, the lysing method with high efficiency was required. The performance of cell lysis 
by freezing and thawing cycles was firstly tested in solution by a glass hemocytomer. 100 
µL cell suspension filled chambers underneath the coverslip, allowing the cell suspension 
to spread out by capillary force. Under the bright field microscope (IX71, Olympus, 
USA), five areas in the grid were selected and live cells were counted. With on average 
of 108 live cells before lysis and 5 cells still alive after freezing and thawing cycles, a 
lysing efficiency of 95% was determined.  
  90 
Next, the cell lysis was performed in microfluidic channels. Cell suspension 
loaded in straight channels by capillary action. After three freezing and thawing cycles, 
images of cells were taken by a bright field microscope. The example images of cells 
before lysis (Figure 6-2a) and after lysis (Figure 6-2b) are shown below. 
  
Figure 6-2: Bright field microscope images of cells resulting from in chip lysis 
experiments (channel width: 100 μm). a) Cells before lysis. b) Cells after lysis. 
 
6.3.2 Influence of Sample Complexity on Detection of Bcl-2 in Cell Lysate  
Bcl-2 is a key protein involved in control of cell apoptosis (Czabotar et al. 2014) 
and of great relevance in biological and clinical studies. Therefore, Bcl-2 was chosen as 
our target protein. Previous studies indicated that Bcl-2 expression was over expressed in 
breast cancer cell line MCF-7 (Kandouz et al. 1996). However, in our case, MALDI MS 
detection of tryptic digested MCF-7 cell lysate ranging from 5 cells/μL to 5×104 cells/µL 
did not show any peptide peaks from Bcl-2 digest (data not shown).  
To investigate if sample complexity in MCF-7 lysate is a factor influencing Bcl-2 
detection, pure Bcl-2 with known concentration (either 140 nM or 14 nM) was spiked in 
MCF-7 cells with various cell concentrations over five orders of magnitude from 5 
cells/µL to 5×10
4
 cells/µL. Results are shown in Figure 6-3 (with 140 nM spiked Bcl-2) 
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and Figure 6-4 (with 14nM spiked Bcl-2). Our previous study showed that the lowest 
concentration of pure Bcl-2 that could be probed was in the nM range (Appendix Figure 
A 2). However, none of Bcl-2 peptides can be probed in 5×10
4
 cells/µL cell lysate for 
140 nM Bcl-2 and none of Bcl-2 peptides can be probed in 5×10
3
 cells/µL cell lysate for 
14 nM Bcl-2. In both cases, signal to noise decreases when concentration of cells 
increases for most of Bcl-2 digest peptides, which further demonstrate that contents in the 
MCF-7 cell lysate reduce the intensity of Bcl-2 peptides. This might be the reason why 
Bcl-2 produced in MCF-7 cells is not detectable. It is interesting to note that not all 
peptides responded in the same way such as peptide m/Z 2295.1 which exhibites higher 
S/N at a cell concentration of 500 cells/µL than 5 cells/µL. A similar phenomenon was 
also reported in a previous study on peptide detection in complex samples (Albalat et al. 
2013). 
In addition, it is clearly seen that peptide m/Z 1210.6 always has the highest S/N 
for detection of 140 nM and 14 nM Bcl-2 in all of the cell concentrations. Thus in all Bcl-
2 quantification experiments with using an isotope labeled peptide, this peptide (m/Z 
1210.6) was chosen as the sample peptide from Bcl-2 digest.  
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Figure 6-3: Signal to noise of Bcl-2 peptides in MCF-7 cell lysate with Bcl-2 (140nM) 
spiked. Three peptides are detected from Bcl-2 digest (Black square: peptide m/Z 1210.6; 
Blue triangle: peptide m/Z 2886.6; Red dot: peptide m/Z 2295.1). 
 
 
Figure 6-4: Signal to noise of Bcl-2 peptides in MCF-7 cell lysate with Bcl-2 (14nM) 
spiked. Three peptides are detected from bcl-2 digest (Black square: peptide m/Z 1210.6; 
Blue triangle: peptide m/Z 2886.6; Red dot: peptide m/Z 2295.1). 
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6.3.3 Bcl-2 Identification and Quantification in Single MCF-7 Cells  
Previously, we designed a novel microfluidic device (ladder-like device) with 
valves for pure Bcl-2 affinity capture, identification by peptides from enzymatic digestion 
and quantification by isotopically labeled peptide. As mentioned above, the detection of 
tryptic digested MCF-7 cell lysate did not show any peptide peaks from Bcl-2 digest. For 
proof of principle, pure Bcl-2 with a detectable concentration (10
-7 
M) was spiked in 
MCF-7 cell lysate (3000 cells/µL). We used this ladder-like device (shown as Figure 6-1a) 
and extended our approach to analyze the spiked Bcl-2 in MCF-7 cell lysate. In our 
approach, cell loading and lysis, Bcl-2 affinity capture as well as enzymatic digestion 
were performed in fluidic channel I (details described in Section 6.2.3). A mixture 
composed of MALDI matrix solution and the reference peptide (an isotope labeled 
peptide) with known concentration filled fluidic channel II of the ladder-like device. 
Thorough mixing of contents in fluidic channel I and II was performed by actuating valve 
B. The Bcl-2 was quantified based on the peak area ratio of sample peptide (m/Z 1210.6) 
and the reference peptide (m/Z 1220.6). 
Since the antibodies were immobilized on the surface when cells were lysed by 
freezing and thawing cycles, the antibodies might be denatured. A control experiment 
was performed in a reservoir to test the binding ability of antibodies after freezing and 
thawing cycles. Similar to the previous affinity capture experiment (described in Section 
4.3.2), Anti-Bcl-2 antibody was immobilized in the reservoir and BSA was applied for 
blocking the unspecific binding positions. After removal of BSA from the channel, the 
reservoir was filled with pure Bcl-2. Next, the chip was placed in -20°C for 3min and 
then 37°C for 3min. This freezing and thawing cycle was repeated for 3 times. 
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Afterwards, the chip was incubated for 1h at room temperature, allowing the binding of 
anti-Bcl-2 and Bcl-2. MALDI matrix was applied to the reservoir before subsequent 
MALDI-TOF analysis. The resulting MS spectrum is shown in Figure 6-5. There are four 
peaks found from Bcl-2, indicating that antibodies can still bind with Bcl-2 after freezing 
and thawing. However, in comparison to the spectrum (Figure 4-3a) obtained in the 
affinity capture experiment but without additional freezing and thawing step, the peaks of 
two digest peptides disappear. This might indicate that the reactivity of anti-Bcl-2 
antibodies is reduced due to freezing and thawing cycles and thus less Bcl-2 is captured 
in this case.  
 
Figure 6-5: MALDI-TOF-MS analysis of an anti-Bcl-2 immunoassay with treating 
antibody by freezing and thawing cycles. Four peptides (red triangle) are found from Bcl-
2 digest. 
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Next, we applied an isotope labeled peptide in our approach to quantify the spiked 
Bcl-2 in MCF-7 cell lysate. The ladder-like device was used in this experiment. 10
-8
 M 
isotope labeled peptide dissolved in MALDI matrix solution was loaded in fluidic 
channel II by vacuum pressure. Components from fluidic channel I and II were mixed by 
repeatedly opening and closing valve B. After the chip was completely dried, the PDMS 
slab was peeled off and the sample on the ITO slide was detected by MALDI-TOF MS. 
This procedure allows the mixing of spiked Bcl-2 digest and 10
-8
 M internal standard 
(isotope labeled peptide). The spiked Bcl-2 was quantified by the peak area ratio of 
sample peptide from Bcl-2 and the isotope labeled peptide. 
Five detection regions (I-V) (shown in Figure 6-1b) in ladder-like devices are 
completely separated, enabling five independent experiments. Moreover, these five 
regions (I-V) from three chips were analyzed by MALDI MS. An example spectrum 
(Figure 6-6) shows both the sample peptide (m/Z [M+H] 1210.6) from Bcl-2 and the 
internal standard (m/Z [M+H]
+
 1220.6). The average peak area ratio of the internal 
standard and the sample peptide was 4.6 (±0.84). With the reference peptide 
concentration of 10
-8
 M and one well volume of 15 nL, we calculated that the number of 
spiked Bcl-2 was 9×10
7 
molecules. However, according to the peak area ratio of 4.6 
(±0.84), the number of spiked Bcl-2 detected in each well was 2.5 (±0.55)×10
7 
molecules, 
indicating that not all spiked Bcl-2 was captured on the anti-Bcl-2 antibody immobilized 
surface.  
 
This might be attributed to several factors. First, the reactivity of anti-Bcl-2 
antibodies is reduced due to freezing and thawing cycles and less Bcl-2 is captured in this 
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case (Figure 6-5). Second, cell lysate masks the Bcl-2 and anti-Bcl-2 binding sites, 
resulting in less Bcl-2 captured. More control experiments are needed to confirm these 
factors and improve the current approach to detect the proteins produced in a single cell. 
Nevertheless, our approach is still promising for single cell analysis since all cell 
handling steps including loading and lysis and the downstream protein analysis steps for 
identification and quantification are successfully coupled in one device. 
 
Figure 6-6: Representative MS spectrum of spiked Bcl-2 detection in MCF-7 cells. (insert: 
zoom in picture of the red rectangular region showing the sample peptide and internal 
standard peptide used for quantification). 
 
6.4 Section Conclusions 
In this chapter, we demonstrated cell lysis by freezing and thawing on chip, which 
was suitable for the downstream protein analysis. Furthermore, with the detection of 
spiked Bcl-2 in various concentrations of MCF-7 cells, we concluded that sample 
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complexity is a factor affecting the detection of Bcl-2 in a cell lysate. This might be the 
reason why Bcl-2 is not detectable in MCF-7 cells. Moreover, cell loading and cell lysis 
were successfully coupled with affinity capture, protein identification and quantification 
on chip. The quantification result showed that not all spiked Bcl-2 was captured by anti-
Bcl-2 immobilized on the surface.  
Our future work involves finding an approach to avoid the problem of Bcl-2 
signal suppressing by other components in the cell lysate. That might be achieved by 
improving the Bcl-2 capturing performance of the immunoassays by applying an 
improved antibody immobilization method. Antibody immobilization with a higher 
surface coverage and more binding sites exposed to the antigen can improve the Bcl-2 
capturing. We also expect to prevent antibody denaturation during the cell lysis by 
alternative methods to freezing and thawing. A possible solution might be adding an 
additional channel to separate the affinity capture and cell lysis step. Beyond that, further 
downscaling our current device is also required to analyze proteins from a single cell. 
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CHAPTER 7 
CONCLUSION AND OUTLOOK 
This work has demonstrated a novel approach for single cell protein analysis 
based on combining a microfluidic platform with MALDI-TOF mass spectrometry. 
Suitable conditions were found to remove the PDMS manifold from the MALDI-MS 
target (ITO slide), allowing the direct coupling of the microfluidic device with MALDI-
TOF mass spectrometry. The detection sensitivity of this approach for peptides was 
found to be ~300 molecules and ~10
6 
copies for proteins which is comparable to the 
amount of high abundant proteins in a single cell.  In addition, an insulin assay was 
successfully coupled in the microfluidic device within areas of ~0.05 mm
2
. Based on our 
estimation, the observed detection limit of insulin is close to the amount of high abundant 
proteins from a single cell or a small cell ensemble. 
Similarly, by using the same approach, Bcl-2 was captured in the immunoassay 
on chip and then detected by MALDI-MS. We improved the detection limit two orders of 
magnitude by probing the peptides formed by the tryptic digestion of Bcl-2. Besides, in 
this way, Bcl-2 could be identified with the human protein database. Next, we presented 
an improved microfluidic device using a series of chambers and valves for absolute 
quantification of target proteins, here Bcl-2, realized by employing two iTRAQ tags. 
Suitable conditions for simultaneous tryptic digestion and iTRAQ labeling have been 
found to achieve iTRAQ quantification on chip. From the quantification results, we 
concluded that for the current immunoassay, a minimum surface area of  ~800 µm
2 
was 
required to capture a high abundant protein from a single cell.  
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The quantification approach was then improved by applying an isotope labeled 
peptide as the internal standard. The MALDI matrix solution could be loaded together 
with the internal standard in the microchannel.  Thus, the sample was not washed out due 
to the renewed filling with the MALDI matrix. Compared with iTRAQ quantification, the 
approach employing an isotope labeled peptide was found to be more reliable due to less 
error sources and variations along the five detection regions.  
Last, the whole approach was applied to analyze spiked Bcl-2 in MCF-7 cells. We 
found that the sample complexity in MCF-7 cells influenced the Bcl-2 detection. 
Furthermore, MCF-7 cell lysis, Bcl-2 affinity capture, Bcl-2 identification and 
quantification were successfully coupled in a microfluidic device to analyze the spiked 
Bcl-2 in MCF-7 cells. Based on the quantification by an isotope labeled peptide, we 
calculated that 2.5 × 10
7 
Bcl-2
 
molecules in MCF-7 cell lysate were detected in each well. 
This quantification result showed that spiked Bcl-2 was not fully captured by anti-Bcl-2 
antibodies immobilized in the channel.  
Future work for improving the current approach can possibly be proceeded with 
the following aspects: 
First, with the integrated immunoassay, we aim in capturing all protein molecules 
apparent in a single cell. This should ideally occur in a well with extremely small surface 
area to prevent dilution. Immobilizing antibodies with high active sites and high surface 
coverage is the key success factor for this purpose. It has been reported that antibodies 
immobilized on the surface often lose their binding ability since the antigen binding sites 
of antibodies may be partially blocked by the substrate surface (Cho et al. 2007). 
Antibodies immobilized with improper orientations can further decrease the binding 
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efficiencies. The ideal orientation is that the antibody is immobilized vertically to the 
surface with the paratopes (antigen binding sites) freely accessible for antigen binding to 
occur. This can be accomplished by using a protein linker which can be directly coupled 
to the surface and bind to the Fc fragment of the antibody.  
For example, the streptavidin-biotin system can provide linkage between the solid 
surface and immunoglobulins (Lee et al. 2005). An antibody can be biotinylated 
randomly on lysine residues by NHS-activated biotin and then immobilized on a 
streptavidin-coated surface (Rowe et al. 2003). When the streptavidin-biotin interaction is 
used to orient the IgGs, the N-linked glycosylation sites on the Fc portion can be oxidized 
and selectively biotinylated by using the biotin-aminooxy compound such as N-
(aminooxyacetyl)-N'-(D-biotinoyl)hydrazine (ARP). Thus, only these biotinylated sites 
can bind to the streptavidin-coated surface, making the Fab region accessible to the 
antigen (Peluso et al. 2003). An alternative antibody (IgG) immobilization can be 
accomplished via protein A and protein G. They can specifically bind to the constant Fc 
region of IgGs. Thus the bound IgGs point away from the immobilization surface, 
leaving the antigen binding region accessible to bind to the antigen (Krenkova and Foret 
2004).  
Second, to enable the antibody immobilization at a higher surface coverage, three-
dimensional materials and polymers can be applied which are expected to result in a 
higher capacity of antibody immobilization than that on two-dimensional surfaces (Perez-
Almodovar and Carta 2009; Tanaka et al. 2009). Shen et al. synthesized a hyperbranched 
polymer (HBP) to improve the antibody immobilization (Figure 7-1). In their strategy, 
protein A reacted with the carboxyl groups of HBP and then the antibody could be 
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immobilized by linking with protein A. Since HBP was a three dimensional polymer 
which contained a high density of carboxyl groups, the amount of immobilized protein A 
was enhanced and thus the antibody binding sites per surface area were increased (Shen 
et al. 2011). 
 
Figure 7-1: A. Synthesis of the hyperbranched polymer used for antibody immobilization. 
B. Procedure for the preparation of the immunosensor. Adapted with permission from 
Shen et al. (Shen et al. 2011). 
 
Third, the matrix/sample cocrystallization conditions can be optimized to improve 
the detection limit of the target protein. One of the factors influencing the sensitivity and 
resolution of MALDI TOF MS analysis is the sample/matrix cocrystallization. Multiple 
stages in the sample preparation can be tuned: 1) The matrix/sample ratio can be 
optimized since the optimum matrix/sample ratios vary by analyte.  2) change the 
MALDI matrix solvent, for example mixing the two components (water and acetonitrile) 
in the right proportions. 3) use improved sample deposition approach such as spin-coated 
MALDI matrix, sprayed MALDI matrix in order to get better homogeneity of the 
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cocrystals. The above factors can be optimized in order to improve the sample/matrix 
cocrystallization and thus decrease the detection limit.  
Fourth, we plan to modify the current device and make it suitable for single cell 
analysis. To prevent dilution, the size of each well needs to be further downscaled, 
comparable to the size of a single cell. In addition, hundreds of wells can be integrated on 
a microfluidic device, allowing for performing hundreds of individual experiments 
simultaneously. In this way, high throughput analysis of single cells can be achieved. 
This novel combined microfluidic and MALDI-TOF mass spectrometric approach 
will eventually be employed for analysis of proteins in single cells. A possible proof-of 
principle could be performed with the analysis of tumor-associated QSOX1 protein on 
the single cell level. QSOX1 has been demonstrated to be over-expressed in pancreas and 
prostate tumor cells and thus represents an excellent target for our study. In addition, 
investigation of protein post-translational modifications is also of interest. For example, 
to study the phosphorylation of a protein, the antibody for the phosphorylated protein can 
be applied for capturing and the above discussed workflow applied to quantify 
phosphorylation on the single cell level. In summary, I predict that our approach will 
provide a novel diagnostic tool for analysis of limited sample amount and open a new era 
of single cell protein analysis. 
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Appendix A 1: Influence of iTRAQ ratios on the quantification of Bcl-2 
The quantification of Bcl-2 on-chip was achieved by using two iTRAQ tags. The 
MS/MS analysis allows for the detection of the iTRAQ labels whereas the peak area ratio 
of 114 tag /117 tag is used to determine unknown concentrations of the peptides and thus 
the corresponding protein. To demonstrate the applicability of the peptide tagging by 
iTRAQ for Bcl-2, digests were differentially labeled with 114 tag and 117 tag. 
Accordingly, 2 µL of 1.4×10-6 M Bcl-2 was mixed with 8 µL iTRAQ dissolution buffer, 
2 µL trypsin solution (0.1mg/mL) and 8 µL iTRAQ tag solution (either 114 tag or 117 
tag). These solutions were incubated at 37°C overnight. The resulting Bcl-2 concentration 
was 1.4×10-7 M which was the same as the reference tag for Bcl-2 in the main 
manuscript. Subsequently, Bcl-2 digests with two labels were mixed in various volume 
ratios. MALDI matrix was added and spotted onto a MALDI target plate. The spots were 
analyzed by using MALDI-TOF/TOF. Figure A 1 shows the peak area ratios derived 
from our experiments versus the expected amount ratios of Bcl-2 digest. An average SD 
of 13.5% was determined  which is in good agreement with Wiese et al (Wiese et al. 
2007). 
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Figure A 1: Linear range between measured peak area ratios of iTRAQ reporter ions 
(m/Z 114.1 and m/Z 117.1) and theoretical amount ratios of differentially labeled Bcl-2 
digest with a slope of 0.98±0.054 and R2 of 0.9923. An average SD of 17% was 
determined (insert: Bcl-2 measurements for different ratios of 114 and 117 tag). 
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Appendix A 2: Detection Sensitivity for Bcl-2  
The concentration range for Bcl-2 detectiction was tested over three orders of 
magnitude. First, direct detection of digested Bcl-2 was performed. Bcl-2 at three 
different concentrations (100 nM, 10 nM, 1 nM) was digested by trypsin. Digests were 
detected by MALDI MS and results are shown in Figure A-3. Second, Bcl-2 in different 
concentrations (100 nM, 10 nM, 1 nM) was used for the Bcl-2 immunoassay and 
digestion experiment on chip (Method details were described in Experimental Section in 
the main manuscript). Results are shown in Figure A 2 and A 3. 
 
Figure A 2: Signal to noise ratio of Bcl-2 peptides after trypsin digest vs. concentration 
for various concentrations of Bcl-2. 
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Figure A 3: Signal to noise ratio of Bcl-2 peptides after affinity capture and digestion on 
chip vs. concentration of Bcl-2. 
 
